glycine has been researched along with ixazomib in 243 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 141 (58.02) | 24.3611 |
| 2020's | 102 (41.98) | 2.80 |
| Authors | Studies |
|---|---|
| Bannerman, B; Berger, A; Blank, J; Bolen, J; Bruzzese, F; Cao, Y; Dick, L; Fitzgerald, M; Fleming, P; Garcia, K; Hales, P; Kupperman, E; Lee, EC; Liu, J; Manfredi, M; Rolfe, M; Tsu, C; Yang, Y; Yu, J; Yu, L | 1 |
| Anderson, KC; Chauhan, D; Kuhn, D; Orlowski, R; Raje, N; Richardson, P; Tian, Z; Zhou, B | 1 |
| Bannerman, B; Bano, K; Berger, AJ; Bolen, JB; Bradley, DP; Carsillo, M; Donelan, J; Fitzgerald, M; Hales, P; Janz, S; Kupperman, E; Lee, EC; Li, P; Li, Z; Liu, R; Manfredi, M; Neppalli, VT; Pickard, M; Silva, MD; Subakan, O; Tayber, O; Terkelsen, J; Van Ness, B | 1 |
| Appel, A | 1 |
| Mullard, A | 1 |
| Amin, SB; Anderson, KC; Berger, AJ; Chauhan, D; Hu, Y; Richardson, P; Tai, YT; Tian, Z; Zhao, JJ | 1 |
| Abe, M; Fujii, S | 1 |
| Hu, Y; Wu, P; Zhang, J | 1 |
| Czuczman, MS; Czuczman, NM; Deeb, G; Gibbs, J; Gu, JJ; Hernandez-Ilizaliturri, FJ; Mavis, C; Patil, R; Skitzki, JJ | 1 |
| Fu, M; Hewitt, E; Lu, Q; Wang, J | 1 |
| Advani, P; Akhtar, D; Chanan-Khan, A; Chitta, K; Colon-Otero, G; Foran, J; Khan, AN; Masood, A; Miller, KC; Paulus, A; Rivera, C; Roy, V | 1 |
| Berger, AJ; Blanco, JF; Canavese, M; Chauhan, D; Fraile, S; Galarraga, M; Garayoa, M; Garcia-Gomez, A; Groen, RW; Hernández-Iglesias, T; Martens, AC; Mateo-Urdiales, J; Ocio, EM; Ortiz-de-Solorzano, C; Quwaider, D; Raje, N; San Miguel, JF; Tian, Z | 1 |
| Cavallo, F; Genadieva-Stavric, S; Palumbo, A | 1 |
| Bensinger, WI; Berenson, JR; Berg, D; Di Bacco, A; Gupta, N; Hui, AM; Kumar, SK; Niesvizky, R; Reeder, CB; Shou, Y; Yu, J; Zimmerman, TM | 1 |
| Baz, R; Berg, D; Di Bacco, A; Gupta, N; Harvey, RD; Hui, AM; Jakubowiak, AJ; Laubach, JP; Liu, G; Lonial, S; Richardson, PG; Talpaz, M; Wang, M; Yu, J | 1 |
| Yagi, H | 1 |
| Diao, P; Lin, X; Lin, Y; Tang, P; Wei, X; Wu, S; Xie, H; Xie, K; Zhou, P | 1 |
| Moreau, P | 1 |
| Assouline, SE; Chang, J; Cheson, BD; Di Bacco, A; Gupta, N; Hamburg, S; Hui, AM; Martin, P; Reyes, R; Rifkin, R; Shou, Y; Yu, J | 1 |
| Esseltine, DL; Gupta, N; Hui, AM; Venkatakrishnan, K; Zhao, Y | 1 |
| Pratt, G | 1 |
| Berdeja, JG; Berg, D; Di Bacco, A; Estevam, J; Gupta, N; Hamadani, M; Hari, P; Hui, AM; Kaufman, JL; Kumar, SK; Laubach, JP; Liao, E; Lonial, S; Niesvizky, R; Rajkumar, V; Richardson, PG; Roy, V; Stewart, AK; Vescio, R | 1 |
| Mitsiades, CS | 1 |
| Berg, D; Berger, AJ; Di Bacco, A; Gao, F; Gupta, N; Hui, AM; Infante, JR; Kalebic, T; Kauh, JS; Lin, J; Liu, G; Siu, LL; Smith, DC; Sullivan, D; Thompson, JA; Tirrell, S; Vlahovic, G | 1 |
| Anderson, KC; Gupta, N; Hui, AM; Kumar, S; Laubach, JP; Moreau, P; Richardson, PG; San Miguel, JF | 1 |
| Amengual, JE; Cooke, L; Cremers, S; Duong, J; Guo, Y; Jirau-Serrano, X; Mahadevan, D; Mangone, M; Mao, Y; Nandakumar, R; O'Connor, OA; Scotto, L; Zullo, KM | 1 |
| Djamali, A; Huang, G; Redfield, RR; Reese, SR; Wilson, NA; Zhong, W | 1 |
| Corvatta, L; Gentile, M; Gentili, S; Morabito, F; Morabito, L; Offidani, M; Recchia, AG; Vigna, E | 1 |
| Gupta, N; Huh, Y; Hui, AM; Hutmacher, MM; Ottinger, S; Venkatakrishnan, K | 1 |
| Bergsagel, PL; Buadi, FK; Chanan-Khan, A; Dispenzieri, A; Fonseca, R; Gertz, MA; Hwa, L; Kapoor, P; Kumar, SK; Lacy, MQ; LaPlant, B; Laumann, K; Mikhael, JR; Rajkumar, SV; Reeder, CB; Rivera, CE; Roy, V; Stewart, AK; Thompson, MA; Witzig, TE | 1 |
| Chim, CS; Chng, WJ; Esseltine, DL; Goh, YT; Gupta, N; Hanley, MJ; Hui, AM; Kim, K; Lee, JH; Min, CK; Venkatakrishnan, K; Wong, RS; Yang, H | 1 |
| Furie, R; Toder, K; Zapantis, E | 1 |
| Corvatta, L; Gentili, S; Leoni, P; Maracci, L; Offidani, M | 1 |
| Garcia, JS; Huang, M; Medeiros, BC; Mitchell, BS | 1 |
| Poh, A | 1 |
| Dikmen, M; Engür, S; Öztürk, Y | 1 |
| Amidon, B; Bannerman, B; Berger, AJ; Bernard, H; Chattopadhyay, N; Donelan, J; Galvin, K; Garnsey, J; Hales, P; Hather, G; Jordan, K; Koenig, E; Maldonado Lopez, A; Manfredi, M; Rhodes, N; Stringer, B; Tirrell, S; Xia, C; Yang, Y | 1 |
| Azab, AK; Ghazarian, RN; Kusdono, HD; Luderer, MJ; Muz, B; Ou, M | 1 |
| Shirley, M | 1 |
| Ratner, M | 1 |
| Bessudo, A; Gupta, N; Hanley, MJ; Hui, AM; Nemunaitis, J; Sharma, S; Venkatakrishnan, K; Wang, B | 1 |
| Abermil, N; Beheshti, A; Coyle, M; Evens, AM; Gartenhaus, RB; Hlatky, L; Kandela, I; Kritharis, A; Mazar, A; Passero, F; Ravi, D; Sharma, J; Sitkovsky, MV | 1 |
| Jung, CK; Jung, Y; Kang, SW; Kim, BG; Kim, TH; Lee, SE; Lim, JY; Min, CK; Park, E; Park, J; Won, KA | 1 |
| Gupta, N; Hui, AM; Labotka, R; Liu, G; Venkatakrishnan, K | 1 |
| Bahlis, NJ; Baker, BW; Berg, DT; Buadi, FK; Cavo, M; Di Bacco, A; Ganly, P; Garderet, L; Gimsing, P; Grzasko, N; Hansson, M; Hui, AM; Jackson, SR; Kumar, S; Laubach, JP; Lin, J; Masszi, T; Moreau, P; Palumbo, A; Pour, L; Richardson, PG; Sandhu, I; Simpson, DR; Stoppa, AM; Touzeau, C; van de Velde, H | 1 |
| Falchook, G; Fu, S; Gupta, N; Hanley, MJ; Labotka, R; Nemunaitis, J; Norris, RE; Perez, R; Qian, MG; Venkatakrishnan, K; Yang, H | 1 |
| Burki, TK | 1 |
| Assouline, S; Calvo-Vidal, MN; Cerchietti, L; Dupéré-Richer, D; Emond, A; Ezponda, T; Guilbert, C; Johnson, NA; Kinal, M; Klein Oros, K; Licht, JD; Mann, KK; Miller, WH; Nichol, JN; Nielsen, TH; Pettersson, F; Plourde, D | 1 |
| Badros, A; Berdeja, J; Chari, A; Gupta, N; Hanley, MJ; Harvey, RD; Hui, AM; Kukreti, V; Lipe, B; Qian, M; Venkatakrishnan, K; Yang, H; Zhang, X | 1 |
| Cao, WM; Cui, Y; Dou, J; Jiang, Z; Wang, H; Wang, Z; Yu, Y; Zhang, H; Zhao, Y | 1 |
| Becker, JP; Clemens, JR; Theile, D; Weiss, J | 1 |
| Moreau, P; Rajkumar, SV | 1 |
| Bourenkov, G; Chari, A; Henneberg, F; Mata, RA; Schneider, TR; Schrader, J; Stark, H; Tittmann, K | 1 |
| Berrios, D; Donoso, P; Montecinos, L; Olmedo, I; Pedrozo, Z; Pezoa, J; Riquelme, JA; Sanchez, G | 1 |
| Dimopoulos, MA; Kastritis, E; Terpos, E | 1 |
| Ailawadhi, S; Bergsagel, PL; Buadi, F; Crawley, J; Dingli, D; Dispenzieri, A; Gertz, MA; Go, RS; Gonsalves, W; Halvorson, AE; Hayman, SR; Hwa, YL; Kapoor, P; Kumar, SK; Lacy, MQ; LaPlant, BR; Lin, Y; Mikhael, J; Rajkumar, SV; Reeder, CB; Rivera, CE; Roy, V; Stewart, K; Thompson, MA; Witzig, TE | 1 |
| Carson, WE; Duggan, MC; Jaime-Ramirez, AC; Karpa, V; Kemper, GM; Luedke, EA; Markowitz, J; Noel, TC; Stiff, A; Suarez-Kelly, LP; Yildiz, VO; Yu, L; Zhang, X | 1 |
| Lonial, S; Panjic, EH; Schlafer, D; Shah, KS | 1 |
| Aubry, MC; Frye, RL; Herrmann, J; Jouni, H; Kumar, SK; Lacy, MQ; Vincent Rajkumar, S | 1 |
| Desai, A; Gong, T; Lu, P; Wang, M; Zeng, D; Zhang, K | 1 |
| Abdel-Mageed, S; Al-Homsi, AS; Cole, K; Feng, Y; Goodyke, A; McLane, M; Muilenburg, M | 2 |
| Boccadoro, M; Bonello, F; Larocca, A; Salvini, M | 1 |
| Chou, T; Handa, H; Ishizawa, K; Kase, Y; Suzuki, K; Takubo, T | 1 |
| Dispenzieri, A; Leung, N; Yui, JC | 1 |
| Davidovich, A; Deng, M; Gordân, R; Kwon, JS; Manandhar, D; Shats, I; Yao, G; You, L; Zhang, C | 1 |
| Bi, Z; Fu, C; Geng, S; Liu, R; Sun, J; Wang, X; Yang, C; Zou, J | 1 |
| Koulaouzidis, G; Lyon, AR | 1 |
| Berg, D; Diderichsen, PM; Gupta, N; Hanley, MJ; Harvey, RD; van de Velde, H; Venkatakrishnan, K | 1 |
| Dikmen, M; Engür, S | 1 |
| Gibson, RJ; Stansborough, RL | 1 |
| Asano, T; Isono, M; Okubo, K; Sato, A | 1 |
| Avivi, I; Berg, D; Einsele, H; Esseltine, DL; Gupta, N; Hájek, R; Hari, P; Kumar, S; Liberati, AM; Lin, J; Lonial, S; Ludwig, H; Masszi, T; Mateos, MV; Minnema, MC; Moreau, P; Richardson, PG; Romeril, K; Shustik, C; Spencer, A | 1 |
| Lei, H; Qiang, YW; Wang, B; Yang, Y | 1 |
| Berg, D; Cohen, AD; Comenzo, RL; Dispenzieri, A; Gupta, N; Hui, AM; Jaccard, A; Kukreti, V; Merlini, G; Palladini, G; Sanchorawala, V; Schönland, SO; Seldin, DC; Yang, H; Zonder, JA | 1 |
| de Wit, E; Moreau, P | 1 |
| Al-Salama, ZT; Garnock-Jones, KP; Scott, LJ | 1 |
| Bonnet, A; Moreau, P | 1 |
| Chen, X; Du, X; Gupta, N; Hanley, MJ; Hou, J; Hua, Z; Jin, J; Ke, X; Li, H; Li, J; Liu, J; Lu, J; Moreau, P; Richardson, PG; van de Velde, H; Wang, B; Wang, H; Wu, D; Xu, Y; Zhang, X; Zhou, D | 1 |
| Bessudo, A; Gupta, N; Hanley, MJ; Nemunaitis, J; O'Neil, BH; Sharma, S; van de Velde, H; Venkatakrishnan, K; Wang, B | 1 |
| Bessudo, A; Esseltine, DL; Gupta, N; Hanley, MJ; Ke, A; Liu, G; Nemunaitis, J; O'Neil, BH; Patel, C; Rasco, DW; Rowland Yeo, K; Sharma, S; Venkatakrishnan, K; Wang, B; Xia, C; Zhang, X | 1 |
| Gupta, N; Hanley, MJ; Kumar, S; Liu, R; Richardson, PG; Skacel, T; Venkatakrishnan, K; Yang, H; Zhang, S | 1 |
| Ma, H; Su, Z; Sun, F; Zhao, N | 1 |
| Bailey, NG; Boonstra, PS; Brown, N; Devata, S; Hristov, AC; Kaminski, MS; Mayer, T; Phillips, T; Polk, A; Wilcox, RA | 1 |
| Chowdhury, S; Gupta, N; Hanley, MJ; Plesescu, M; Pusalkar, S; Shepard, DR; Venkatakrishnan, K; Wang, B; Xia, C; Zhang, S; Zhang, X | 1 |
| Avet-Loiseau, H; Bahlis, NJ; Ben-Yehuda, D; Berg, D; Cavo, M; Chng, WJ; di Bacco, A; Esseltine, DL; Ganly, P; Kumar, S; Langer, C; Lin, J; Masszi, T; Moreau, P; Nagler, A; Palumbo, A; Pluta, A; Pour, L; Rajkumar, SV; Richardson, PG; San-Miguel, J; van de Velde, H; Viterbo, L | 1 |
| Allen, JE; Babar, J; Benes, CH; Claxton, DF; Dicker, DT; El-Deiry, WS; Garnett, MJ; Grupp, SA; Hall, J; Khan, N; Kline, CLB; Lulla, AR; McDermott, U; Oster, W; Prabhu, VV; Pu, JJ; Talekar, MK; Van den Heuvel, APJ; Zhou, L | 1 |
| Guo, H; Sun, X; Wang, B; Xu, W | 1 |
| Barley, K; Barlogie, B; Chari, A; Cho, HJ; Jagannath, S; Lancman, G; Madduri, D; Moshier, E; Parekh, S; Tremblay, D | 1 |
| Costello, C; Mikhael, JR | 1 |
| Boccadoro, M; Giudice, D; Larocca, A; Pautasso, C; Salvini, M; Troia, R | 1 |
| Corvatta, L; Gentili, S; Offidani, M | 1 |
| Augello, G; Azzolina, A; Cassata, G; Cervello, M; Cusimano, A; Di Sano, C; Emma, MR; Modica, M; Montalto, G; Puleio, R | 1 |
| Alloo, A; Castillo, JJ; Granter, SR; Jadeja, SM; Khosravi, H; LeBoeuf, NR; Richardson, PG | 1 |
| Berg, D; Diderichsen, PM; Gupta, N; Hanley, MJ; Ke, A; Labotka, R; Liu, G; Patel, C; Teng, Z; van de Velde, H; Venkatakrishnan, K; Yang, H | 1 |
| Moreau, P; Touzeau, C | 1 |
| Grammatico, S; Petrucci, MT; Scalzulli, E; Vozella, F | 1 |
| Ashcroft, AJ; Boardman, K; Cairns, DA; Cavenagh, J; Cook, G; Cook, M; Drayson, MT; Garg, M; Hockaday, A; Jacques, G; Owen, R; Snowden, JA; Striha, A; Williams, C; Yong, K | 1 |
| Armoiry, X; Clarke, A; Connock, M; Cummins, E; Melendez-Torres, GJ; Royle, P; Tsertsvadze, A | 1 |
| Jun, Y; Kim, KB; Lee, W; Miller, Z; Park, JE | 1 |
| Chendamarai, E; DiPersio, JF; Eissenberg, L; Ghobadi, A; Holt, MS; Kennerly, K; Rettig, MP; Ritchey, JK | 1 |
| Berg, D; Hari, P; Lin, HM; Moreau, P; Richardson, PG; Zhu, Y | 1 |
| Badran, K; Bailey, ST; Bernthal, NM; Braas, D; Christofk, HR; Demo, S; Dubinett, SM; Federman, N; Fishbein, MC; Fridman, D; Go, J; Graeber, TG; Gricowski, M; Ibarra, J; Lee, JT; Li, R; Momcilovic, M; Parlati, F; Phelps, ME; Sadeghi, S; Shackelford, DB; Shuman, R; St John, M; Walser, TC; Yanagawa, J | 1 |
| Annunziata, CM; Nunes, AT | 1 |
| Bacco, AD; Baz, R; Berdeja, JG; Berg, D; Byrne, C; Chari, A; Estevam, J; Gupta, N; Hofmeister, CC; Htut, M; Lebovic, D; Liao, E; Liedtke, M; Raje, N; Richardson, PG; Rosenbaum, CA; Smith, SD; Vesole, DH | 1 |
| Hasinoff, BB; Patel, D | 1 |
| Joseph, NS; Kaufman, JL | 1 |
| Hawkins, CJ; Patatsos, K; Shekhar, TM | 1 |
| Bargou, RC; Barrio, S; Barrio-Garcia, C; Beckmann, R; Besse, A; Braggio, E; Chatterjee, M; Cuenca, I; Da-Viá, M; Driessen, C; Einsele, H; Fink, S; Garitano-Trojaola, A; Kortüm, KM; Lehners, N; Leich, E; Martinez-Lopez, J; Raab, MS; Rosenwald, A; Stewart, AK; Stühmer, T | 1 |
| Aardsma, N; Chen, YH; Crispino, JD; Frankfurt, O; Gartel, AL; Halasi, M; Kalakota, N; Khan, I; Liu, L; Mahmud, N; Patel, A; Schultz, R | 1 |
| Gupta, N; Hanley, MJ; Harvey, RD; Labotka, R; Venkatakrishnan, K; Xia, C | 1 |
| Chowdhury, S; Gupta, N; Hanley, M; Plesescu, M; Pusalkar, S; Venkatakrishnan, K; Wu, JT; Xia, C; Zhang, X | 1 |
| Abeykoon, JP; Kapoor, P; Zanwar, S | 1 |
| Agarwal, N; Johnson, R; McCabe, P | 1 |
| Bradley, D; Chattopadhyay, N; Gibb, A; Golay, X; Johnson, SP; Lythgoe, MF; Pedley, RB; Ramasawmy, R; Taylor, V; Walker-Samuel, S; Zhu, Y | 1 |
| Sun, X; Yue, D | 1 |
| Balic, M; Bartsch, R; Burgstaller, S; Egle, D; Fuchs, D; Gampenrieder, SP; Greil, R; Melchardt, T; Mlineritsch, B; Petru, E; Petzer, A; Rinnerthaler, G; Rossmann, D; Rumpold, H; Singer, CF; Ulmer, H | 1 |
| Ferrari, RH; Kumar, SK; Laubach, JP; Lonial, S; O'Donnell, EK; Raje, N; Richardson, PG; Skacel, T; Voorhees, P; Zweegman, S | 1 |
| Byrne, C; Delimpasi, S; Dimopoulos, MA; Grosicki, S; Grzasko, N; Gupta, N; Jedrzejczak, WW; Kumar, SK; Kyrtsonis, MC; Labotka, R; Spencer, A; Teng, Z | 1 |
| Byrne, C; Dimopoulos, MA; Grosicki, S; Gruber, A; Grzasko, N; Gupta, N; Hansson, M; Jędrzejczak, WW; Kumar, S; Labotka, R; Nahi, H; Teng, Z; Yang, H | 1 |
| Alleboina, S; Balusu, R; Ganguly, S; Jensen, RA; Kuravi, S; McGuirk, JP; Mudduluru, G | 1 |
| van de Donk, NWCJ; Yong, K | 1 |
| Beksac, M; Chng, WJ; Dash, AB; Dimopoulos, MA; Gay, F; Goldschmidt, H; Gupta, N; Hajek, R; Iida, S; Kaiser, M; Labotka, R; Maisnar, V; Mateos, MV; Min, CK; Moreau, P; Morgan, G; Palumbo, A; Pluta, A; Rajkumar, SV; Schjesvold, F; Skacel, T; Spencer, A; Suryanarayan, K; Teng, Z; Weisel, KC; Zweegman, S | 1 |
| Jiang, J; Liang, Z; Wan, N; Xie, J; Zhang, T | 1 |
| Berdeja, JG; Berg, D; Hamadani, M; Hari, P; Kaufman, JL; Kumar, SK; Laubach, JP; Liao, E; Lonial, S; Niesvizky, R; Rajkumar, SV; Richardson, PG; Roy, V; Stewart, AK; Vescio, R | 1 |
| Alizadeh, H; Bátai, Á; Deák, B; Demeter, J; Illés, Á; Kosztolányi, S; Mikala, G; Nagy, Z; Pető, M; Plander, M; Schneider, T; Szendrei, T; Szomor, Á; Varga, G; Váróczy, L | 1 |
| Antunes, L; Bento, MJ; Chacim, S; Lefèvre, C; Pereira, M; Pereira, S; Rocha-Gonçalves, F; Zagorska, A | 1 |
| Hall, KH | 1 |
| Chang, TK; Cho, HS; Jung, CR; Kang, HM; Lim, JH; Noh, KH; Park, D | 1 |
| Rydygier, D; Smolewski, P | 1 |
| Berg, D; Byrne, C; Dimopoulos, MA; Echeveste Gutierrez, MA; Grzasko, N; Hofmeister, CC; Kumar, S; Labotka, R; Laubach, JP; Liu, G; Lu, V; Richardson, PG; San-Miguel, JF; Teng, Z; van de Velde, H | 1 |
| Bargou, RC; Brünnert, D; Chatterjee, M; Driessen, C; Goyal, P; Heiden, R; Kirner, S; Kraus, M; Stühmer, T | 1 |
| Advani, AS; Caimi, P; Carew, J; Carraway, H; Chan, R; Cooper, B; de Lima, M; Elson, P; Gerds, A; Hamilton, B; Kalaycio, M; Little, J; Maciejewski, J; Malek, E; Miron, A; Mukherjee, S; Nazha, A; Pink, J; Sekeres, MA; Sobecks, R; Tomlinson, B; Unger, A; Visconte, V; Wei, W | 1 |
| Cai, H; Li, N; Liu, M; Zhang, L; Zheng, B | 1 |
| Araki, T; Fujitani, Y; Miura, A; Ohta, K; Takakuwa, T; Takeoka, Y; Yamamura, R | 1 |
| Comenzo, R; Lentzsch, S; Premkumar, V | 1 |
| Beheshti, A; David, KA; Evens, AM; McDonald, JT; Passero, FC; Ravi, D | 1 |
| Nohgawa, M; Oka, S; Ono, K | 1 |
| He, R; Kong, L; Xi, J; Zhang, J; Zhu, H; Zhuang, R | 1 |
| Coccia, M; Lanzilli, G; Pizzato Scomazzon, S; Riccio, A; Rossi, A; Santopolo, S; Santoro, MG | 1 |
| Egle, A; Einsele, H; Greil, R; Gunsilius, E; Hajek, R; Hinke, A; Jelinek, T; Knop, S; Krenosz, KJ; Lechner, D; Ludwig, H; Meckl, A; Melchardt, T; Niederwieser, D; Nolte, S; Petzer, A; Pönisch, W; Pour, L; Rumpold, H; Schreder, M; Weisel, K; Willenbacher, W; Zojer, N | 1 |
| Egle, A; Einsele, H; Greil, R; Gunsilius, E; Hajek, R; Knop, S; Krenosz, KJ; Lechner, D; Ludwig, H; Melchardt, T; Niederwieser, D; Petzer, A; Poenisch, W; Schreder, M; Weisel, K; Willenbacher, W; Zojer, N | 1 |
| Ito, S; Shinagawa, A; Suyama, T | 1 |
| Abildgaard, N; Cain, L; Dimopoulos, M; Gnanasakthy, A; Goldschmidt, H; Maisnar, V; Odom, D; Rajkumar, V; Romanus, D; Rowlings, P; Schjesvold, F; Spicka, I; Suryanarayan, K | 1 |
| Cheesman, S; Cohen, OC; Fontana, M; Gillmore, JD; Hawkins, PN; Kyriakou, C; Lachmann, HJ; Mahmood, S; Martinez-Naharro, A; Popat, R; Rabin, N; Sachchithanantham, S; Shah, R; Sharpley, F; Wechalekar, AD; Whelan, CJ; Yong, K | 1 |
| Chung, D; Diab, V; Drullinsky, P; Giralt, S; Hassoun, H; Hultcrantz, M; Korde, N; Lahoud, O; Landau, H; Landgren, O; Lendvai, N; Lesokhin, A; Mailankody, S; Mastey, D; Salcedo, M; Schlossman, J; Scordo, M; Shah, G; Shah, U; Smith, E; Werner, K | 1 |
| Bao, R; He, L; Ju, Y; Li, C; Luo, Y; Sang, Z; Song, R; Sun, K; Yang, T; Yang, Y; Zhou, Y | 1 |
| Li, J; Sherman, DJ | 1 |
| Broaddus, R; Fu, S; Hess, K; Hong, D; Janku, F; Karp, D; Kopetz, S; Liu, L; Naing, A; Overman, M; Piha-Paul, S; Shi, N; Subbiah, V; Tsimberidou, AM; Wang, Y; Yao, J | 1 |
| Chung, DJ; Diamond, B; Lesokhin, AM; Maclachlan, K; Ola Landgren, C | 1 |
| Avet-Loiseau, H; Badola, S; Bahlis, NJ; Berg, D; Cavo, M; Di Bacco, A; Esseltine, DL; Ganly, P; Keats, JJ; Kumar, SK; Langer, C; Li, B; Lin, J; Luptakova, K; Masszi, T; Moreau, P; Munshi, NC; Pour, L; Rajkumar, SV; Richardson, PG; Shen, L; van de Velde, H; Viterbo, L; Zhang, J | 1 |
| Avivi, I; Chubar, E; Cohen, YC; Gatt, ME; Horowitz, N; Kreiniz, N; Lavi, N; Magen, H; Rouvio, O; Shaulov, A; Shvetz, O; Tadmor, T; Trestman, S; Vitkon, R; Ziv-Baran, T | 1 |
| Agha, A; Ali, AA; Debiec-Rychter, M; Dhillon, HS; Duensing, A; Gebreyohannes, YK; Lee, DM; Makielski, KR; Mehalek, KR; Patil, SS; Rausch, JL; Schöffski, P; Tolstov, Y; Wellens, J; Wozniak, A | 1 |
| Aitchison, R; Dimopoulos, MA; Gavriatopoulou, M; Hajek, R; Jelinek, T; Jenner, MW; Kastritis, E; Katodritou, E; Kothari, J; Kotsopoulou, M; Maouche, N; Minarik, J; Ntanasis-Stathopoulos, I; Pika, T; Plonkova, H; Ramasamy, K; Terpos, E; Vallance, GD; Zomas, A | 1 |
| Fajardo, S; Zink, KA | 1 |
| Cavo, M; Chng, WJ; Dimopoulos, MA; Goldschmidt, H; Labotka, R; Mateos, MV; Mikala, G; Moreau, P; Rajkumar, SV; Ramasamy, K; Suryanarayan, K; Teng, Z; Weisel, KC | 1 |
| Avet-Loiseau, H; Bahlis, NJ; Berg, D; Dash, AB; Di Bacco, A; Li, B; Lin, J; Moreau, P; Richardson, PG; Shen, L; Zhang, J | 1 |
| Chen, S; He, Y; Hu, J; Jiang, D; Zhang, K; Zhu, Y; Zou, L | 1 |
| Guo, SL; Li, Z; Wang, WL | 1 |
| Ahumada, X; Chalmers, S; Donoso, P; Eisner, V; Kogan, MJ; Lavandero, S; Montecinos, L; Olmedo, I; Pedrozo, Z; Riveros, A; Sánchez, G | 1 |
| Bhatt, VR; Hall, AM; Hamilton, B; Lee, SJ; Onstad, L; Pidala, J; Pusic, I; Storer, B; Wood, WA | 1 |
| Riccio, A; Rossi, A; Santopolo, S; Santoro, MG | 1 |
| Beksaç, M; Czorniak, M; de Arriba de la Fuente, F; Dimopoulos, MA; Gulbrandsen, N; Hájek, R; Kaiser, M; Labotka, R; Li, C; Mateos, MV; Moreau, P; Rajkumar, SV; Schjesvold, F; Spencer, A; Suryanarayan, K; Teng, Z; West, S | 1 |
| Abedin, S; Chhabra, S; D'Souza, A; Dhakal, B; Douglas Rizzo, J; Drobyski, WR; Fenske, TS; Hamadani, M; Hari, PN; Horowitz, MM; Jerkins, JH; Pasquini, MC; Runaas, L; Saber, W; Shah, NN; Shaw, BE; Tang, X; Thompson, R; Visotcky, A; Zhang, MJ; Zhu, F | 1 |
| Boiten, HJ; Buijze, M; Levin, MD; Zweegman, S | 1 |
| Alameda, D; Alignani, D; Bargay, J; Blade, J; Burgos, L; Calasanz, MJ; Cedena, MT; Celay, J; Cordón, L; de la Rubia, J; Flores-Montero, J; Fresquet, V; Garcés, JJ; Garcia-Sanz, R; Goicoechea, I; Gutierrez, NC; Hernandez, MT; Krsnik, I; Lahuerta, JJ; Lara-Astiaso, D; Martin-Sanchez, J; Martinez-Climent, JA; Martinez-Lopez, J; Martinez-Martinez, R; Mateos, MV; Moraleda, JM; Orfao, A; Oriol, A; Paiva, B; Palomera, L; Puig, N; Ramos, MM; Rios, R; Rodriguez, I; Rodriguez, S; Rosiñol, L; San Miguel, J; Sarra, J; Sarvide, S; Vidriales, MB; Vilas-Zornoza, A | 1 |
| Gonzalez-McQuire, S; Lebioda, A; Poenisch, W; Rieth, A; Schoehl, M; Singh, M; Steinmetz, HT | 1 |
| Bashey, A; Brown, S; Holland, HK; Jackson, KC; Morris, LE; Solh, M; Solomon, SR; Zhang, X | 1 |
| Kanbur, E; Stanley, BA; Tümer, E; Yerlikaya, A | 1 |
| Castillo, JJ; Chen, J; Demos, MG; Flynn, CA; Guerrera, ML; Hunter, Z; Kofides, A; Liu, X; Meid, K; Munshi, M; Patterson, CJ; Treon, SP; Tsakmaklis, N; Yang, G | 1 |
| Bao, L; Chen, B; Ding, K; Fu, C; Hua, L; Huang, Y; Li, B; Li, J; Liu, P; Luo, J; Wang, L; Wang, S; Wang, W; Wu, G; Xia, Z; Xu, T; Yang, W; Yang, Y; Zhang, W; Zhou, X | 1 |
| Kamiya, T; Kato, J; Kikuchi, T; Mizuno, K; Mori, T; Nakayama, H; Okamoto, S; Okayama, M; Shimizu, T | 1 |
| Aiello, J; Birhiray, RE; Boccia, R; Bogard, K; Charu, V; Cherepanov, D; Demers, B; Ferrari, RH; Girnius, S; Jhangiani, HS; Kambhampati, S; Lu, V; Lyons, R; Manda, S; Noga, SJ; Rifkin, RM; Whidden, P; Yasenchak, CA; Yimer, HA | 1 |
| Chiba, M; Fukumoto, S; Hoshikawa, S; Inuzuka, H; Saito, K; Shimizu, K; Watahiki, A; Wei, W | 1 |
| Auner, HW; Bailey, L; Brown, S; Brudenell Straw, F; Cook, G; Cook, M; Dawkins, B; Flanagan, L; Hinsley, S; Kaiser, MF; McKee, S; Meads, D; Reed, S; Sherratt, D; Walker, K | 1 |
| Beksac, M; Bringhen, S; Chng, WJ; Dimopoulos, MA; Garg, M; Hájek, R; Iida, S; Katodritou, E; Labotka, R; Leleu, X; Lonial, S; Mateos, MV; Morgan, G; Oriol, A; Palumbo, A; Quach, H; Špička, I; Vorog, A; Wang, B | 1 |
| Chen, Z; Li, R; Ling, Y; Zhao, Y; Zhong, J | 1 |
| Ma, W; Zhang, L; Zhao, J | 1 |
| Chen, Y; Jiang, L; Jin, F; Liu, L; Yang, M | 1 |
| Ailawadhi, S; Alegria, V; Chanan-Khan, AA; Parrondo, RD; Roy, V; Sher, T | 1 |
| Abildgaard, N; Axelsson, P; Blimark, C; Hansson, M; Haukas, E; Hieu Do, T; Klein, SK; Klostergaard, A; Knut-Bojanowska, D; Levin, MD; Leys, RBL; Mellqvist, UH; Poddighe, PJ; Salomo, M; Schjesvold, FH; Sonneveld, P; Stege, CAM; Stevens-Kroef, M; Svirskaite, A; Szatkowski, D; van de Donk, NWCJ; van der Holt, B; van der Spek, E; Waage, A; Ypma, PF; Zweegman, S | 1 |
| Bertassoli, BM; Carvalho, AAS; Feder, D; Fonseca, FLA; Hermes, TA; Micheletto, MLJ; Perez, MM; Petri, G | 1 |
| Aitchison, R; Bhatti, Z; Bird, SA; Boyd, K; Bygrave, C; Chander, G; Collings, F; Dungarwalla, M; Jenner, MW; Kishore, B; Kothari, J; Maouche, N; Offer, M; Peniket, A; Ramasamy, K; Robinson, R; Vallance, GD | 1 |
| Cheesman, S; De-Silva, D; Kyriakou, C; Lawson, G; Mahmood, S; Papanikolaou, X; Popat, R; Rabin, N; Sachchithananthan, S; Sive, J; Wechalekar, A; Yong, K; Ziff, M | 1 |
| Bacovsky, J; Brozova, L; Capkova, L; Hajek, R; Heindorfer, A; Jelinek, T; Jindra, P; Jungova, A; Kessler, P; Krhovska, P; Machalkova, K; Maisnar, V; Minarik, J; Mistrik, M; Pavlicek, P; Pika, T; Plonkova, H; Pour, L; Radocha, J; Skacel, T; Spicka, I; Stejskal, L; Stork, M; Straub, J; Sykora, M; Ullrychova, J | 1 |
| Adachi, Y; Fuchida, SI; Hanamoto, H; Hino, M; Imada, K; Kanakura, Y; Kanda, J; Kaneko, H; Kosugi, S; Kuroda, J; Matsuda, M; Matsumura, I; Nakaya, A; Nomura, S; Ohta, K; Onda, Y; Shibayama, H; Shimazaki, C; Shimazu, Y; Shimura, Y; Takakuwa, T; Takaori-Kondo, A; Tanaka, H; Uchiyama, H; Uoshima, N; Yagi, H; Yamamura, R; Yoshihara, S | 1 |
| Asmis, R; Butler, MJ; Cortez, V; Esparza, J; Fan, H; Habib, SL; Kinney, MC; Medina, EA; Nguyen, HN; Oyajobi, BO; Polusani, SR; Velagaleti, GVN | 1 |
| Alsuliman, T; Bonnin, A; Ikhlef, S; Lemoine, J; M'Hammedi-Bouzina, F; Malard, F; Marjanovic, Z; Mohty, M; van de Wyngaert, Z | 1 |
| Chen, X; Chen, Y; Dong, Z; Huang, J; Ma, L; Su, J; Tian, L; Wang, Q; Xiao, P | 1 |
| Danesi, R; Del Re, M; Fogli, S; Galimberti, S; Gori, V | 1 |
| Ayuda-Durán, P; Enserink, JM; Grad, I; Hanes, R; Kuijjer, ML; Meza-Zepeda, LA; Myklebost, O | 1 |
| Bahlis, NJ; Benboubker, L; Facon, T; Karlin, L; Kumar, SK; Lonial, S; Moreau, P; Offner, F; Rajkumar, SV; Richardson, PG; Rifkin, RM; Rigaudeau, S; Rodon, P; Shibayama, H; Suzuki, K; Twumasi-Ankrah, P; Venner, CP; Voog, E; White, DJ; Yoon, SS; Yung, G; Zhang, X | 1 |
| Cloos, J; Jansen, G; Kaspers, GJL; Kwidama, ZJ; Roeten, MSF; Segerink, WH; Ter Huizen, G; van Meerloo, J; Zweegman, S | 1 |
| Bhutani, D; Cespedes, DA; Gallitano, SM | 1 |
| Bilgin, YM; de Graauw, NCHP; de Waal, EGM; Durdu-Rayman, N; Geerts, PAF; Kentos, A; Klein, SK; Levin, MD; Ludwig, I; Nasserinejad, K; Nijhof, IS; Oosterveld, M; Silbermann, MH; Soechit, S; Sohne, M; Sonneveld, P; Stege, CAM; Thielen, N; Timmers, GJ; van de Donk, NWCJ; van der Klift, M; van der Spek, E; van Kampen, RJW; Vekemans, MC; Zweegman, S | 1 |
| Abonour, R; Berdeja, J; Blazer, M; Boccadoro, M; Chari, A; Cherepanov, D; Cook, G; Costello, C; Davies, F; Farrelly, E; Hajek, R; Huang, H; Lee, HC; Leleu, X; Morgan, G; Palumbo, A; Puig, N; Raju, A; Rifkin, R; Romanus, D; Stull, DM; Terpos, E; Thompson, M; Usmani, S; Vela-Ojeda, J; Weisel, K; Zonder, J | 1 |
| Bergin, K; Kalff, A; Reynolds, J; Sirdesai, S; Spencer, A; Wallington-Beddoe, C; Yuen, F | 1 |
| Cho, C; Dahi, P; Devlin, SM; Flynn, L; Giralt, S; Lee, J; Murray, F; Perales, MA; Ponce, DM; Rodriguez, N; Sauter, C; Soto, C | 1 |
| Busch, M; Downey-Kopyscinski, SL; Esdar, C; Friese-Hamim, M; Gaus, S; Klein, M; Mitsiades, CS; Musil, D; Rohdich, F; Sanderson, MP; Schadt, O; Walter-Bausch, G; Zanelli, U | 1 |
| Bolaman, Z; Yavaşoğlu, İ | 1 |
| Aslam, M; Atenafu, EG; Cherniawsky, H; Gul, E; Jimenez-Zepeda, VH; Kotb, R; LeBlanc, R; Louzada, ML; Masih-Khan, E; McCurdy, A; Reece, DE; Reiman, A; Sebag, M; Song, K; Stakiw, J; Venner, CP; White, D | 1 |
| Berg, D; Comenzo, RL; Dispenzieri, A; Faller, DV; Kastritis, E; Kim, K; Kumar, A; Kwok, F; Landau, HJ; Liu, G; Merlini, G; Sanchorawala, V; Schönland, SO; Suzuki, K; Wechalekar, AD | 1 |
| Harousseau, JL; Mohty, M | 1 |
| Adashek, JJ; Brown, EJ; Fu, S; Hong, DS; Karp, DD; Kato, S; Nguyen, L; Piha-Paul, SA; Subbiah, V; Sun, M; Yap, TA | 1 |
| Alizadeh, H; Demeter, J; Hardi, A; Illés, Á; Kosztolányi, S; Masszi, T; Mikala, G; Nagy, Z; Plander, M; Schneider, T; Varga, G; Váróczy, L | 1 |
| Chudej, J; Guman, T; Hlebaskova, M; Kucerikova, M; Sokol, J; Stasko, J; Stecova, N; Valekova, L | 1 |
| Barbado, MV; Caballero-Velázquez, T; Caracuel-García, R; García-Guerrero, E; Nufer, M; Pérez-Simón, JA; Ramos, TL; Robles-Frías, MJ; Rodríguez-Gil, A | 1 |
| Bova-Solem, M; Carlisle, D; Efebera, YA; Hassoun, H; Laubach, JP; McCarthy, PL; Mulkey, F; Richardson, PG; Santo, K; Suman, VJ; Tuchman, SA; Voorhees, PM | 1 |
| Berg, D; Chou, T; Fukunaga, S; Iida, S; Ikeda, T; Izumi, T; Komeno, T; Sasaki, M; Sugiura, K; Terui, Y | 1 |
| Chou, T; Hashimoto, M; Hiraizumi, M; Hoshino, M; Kakimoto, Y; Shimizu, K | 1 |
| Fan, S; Huang, Z; Li, X; Shen, M; Tang, R; Wang, Y; Zhan, X; Zhang, J; Zhong, Y | 1 |
| Chen, H; Chen, L; Li, Q; Qi, H; Shi, X; Wang, T; Zhang, L; Zhang, P; Zhong, M; Zhu, Y | 1 |
| Besse, A; Besse, L; Bornhauser, B; Bourquin, JP; Driessen, C; Kraus, M; Maurits, E; Overkleeft, HS | 1 |
| Anderman, MF; Bhargava, D; Boccuzzi, L; de Miguel, FJ; Doroshow, JH; Durkin, ME; Lowy, DR; Papageorge, AG; Politi, K; Qian, X; Tripathi, BK; Walters, KJ; Wang, D | 1 |
| Aquino, S; Ballanti, S; Belotti, A; Boccadoro, M; Bonello, F; Bringhen, S; Capra, A; Cea, M; Cellini, C; Ciccone, G; Corradini, P; De Paoli, L; De Sabbata, G; Falcone, AP; Grasso, M; Larocca, A; Liberati, AM; Mina, R; Monaco, F; Musolino, C; Offidani, M; Paris, L; Patriarca, F; Pescosta, N; Petrucci, MT; Rota-Scalabrini, D; Tacchetti, P; Zambello, R | 1 |
| Hipolito, CJ; Song, L; Tan, Y; Wang, S; Wu, C; Wu, J; Yin, Y; Zhang, M; Zhang, Y | 1 |
| Chen, H; Shao, C; Sun, C; Wang, Y; Zheng, C | 1 |
| Fu, CC; Jin, S; Shang, JJ; Wang, J; Wu, DP; Yan, Z; Yao, Y | 1 |
| Bashir, Q; Feng, L; Huo, XJ; Lee, HC; Manasanch, EM; Morphey, A; Olsem, J; Orlowski, RZ; Patel, KK; Qazilbash, MH; Shah, JJ; Thomas, SK; Weber, DM | 1 |
| Darif, M; Demarquette, H; Dimopoulos, MA; Doronin, V; Du, J; Fenk, R; Kumar, S; Labotka, R; Lee, C; Leleu, X; Levin, MD; Mellqvist, UH; Montes, YG; Pompa, A; Quach, H; Ramasamy, K; Sati, H; Schjesvold, F; Vinogradova, O; Vorog, A | 1 |
| Amrein, P; Ballen, K; Behnam, T; Bergeron, M; Bertoli, C; Blonquist, T; Brunner, A; Burke, M; Connolly, C; Fathi, A; Foster, J; Hobbs, G; Hock, H; Lombardi Story, J; Macrea, M; McAfee, S; McGreggor, K; Moran, J; Neuberg, D; Ramos, A; Som, T; Stevenson, K; Vartanian, M | 1 |
| Attal, M; Benboubker, L; Chretien, ML; Dejoie, T; Facon, T; Hulin, C; Jacquet, C; Karlin, L; Leleu, X; Loiseau, HA; Manier, S; Mohty, M; Moreau, P; Perrot, A; Planche, L; Roussel, M; Tiab, M; Touzeau, C | 1 |
| Bachanek-Mitura, O; Chocholska, S; Czabak, O; Hus, M; Mlak, R; Muzyka-Kasietczuk, J; Szczyrek, M; Szudy-Szczyrek, A | 1 |
| Auner, HW; Brown, SR; Cook, G; Cook, M; Dawkins, B; Kaiser, MF; Kendall, J; Meads, D; Morgan, GJ; Parrish, C; Roberts, S; Walker, K | 1 |
| Aepfelbacher, M; Betzel, C; Hinrichs, W; Perbandt, M; Prester, A; Rohde, H; Werner, N | 1 |
| Berenson, JR; Bessudo, A; Bitran, JD; Chen, G; Cohen, A; Daniely, D; Eades, BM; Eshaghian, S; Forouzan, E; Hrom, J; Kim, C; Lim, S; Moezi, MM; Spektor, TM; Swift, RA | 1 |
| Fujiwara, M; Muroi, N; Shimizu, T; Uchida, M; Uesawa, Y; Yamaoka, K | 1 |
| Diderichsen, PM; Gupta, N; Hanley, MJ; Labotka, R; Srimani, JK; Venkatakrishnan, K | 1 |
| Cheng, H; Cheng, P; Guan, J; Wang, LL; Wang, QX; Zhou, Y; Zou, L | 1 |
| Bergsagel, PL; Bradt, EE; Buadi, FK; Dingli, D; Dispenzieri, A; Fonder, A; Gertz, MA; Go, RS; Gonsalves, W; Hayman, SR; Helgeson, DK; Hobbs, M; Hwa, YL; Kapoor, P; Kourelis, TV; Kumar, SK; Lacy, MQ; LaPlant, BR; Larsen, JT; Leung, N; Muchtar, E; O'Brien, P; Rajkumar, SV; Siddiqui, M; Warsame, R | 1 |
| Abrahams, A; Hassoun, H; Lagdameo, J; Lahoud, O; Landau, HJ; Niesvizky, R; Osman, K; Özbek, U; Rosenbaum, CA; Sanchez, L | 1 |
| Ding, C; He, Y; Liu, Y; Peng, H; Qi, Z; Ren, H; Tang, H; Tang, W; Wang, J; Xia, B; Zhao, L; Zhao, P; Zheng, X | 1 |
| Aotsuka, Y; Kano, H; Kuwabara, S; Mimura, N; Misawa, S; Morooka, M; Nakamura, K; Ohwada, C; Otani, R; Sakaida, E; Sekiguchi, Y; Shibuya, K; Suichi, T; Takeda, Y; Tsukamoto, S | 1 |
| Bao, S; Chai, G; Chen, X; Liu, C; Mao, J; Zhi, Y; Zhu, J | 1 |
| Goel, U; Kumar, S | 1 |
| Appelmann, I; Brümmendorf, TH; Koschmieder, S; Maletzke, S; Masouleh, BK; Salimi, A; Schemionek, M; Schroeder, KM; Vieri, M | 1 |
| Hatokova, P; Melnikova, I; Piskackova, HB; Roh, J; Sestak, V; Sterbova-Kovarikova, P | 1 |
| Yang, C; Zhuang, JL | 1 |
| Deng, M; Liu, S; Peng, H; Wang, Z; Xiao, H; Xiao, X; Yuan, H; Zhang, G | 1 |
| Aziz, F; Cascalho, M; Denham, S; Djamali, A; Hematti, P; Jucaud, V; Mishra, A; Parajuli, S; Platt, JL; Ptak, L; Reese, S; Wilson, N | 1 |
| Chen, Y; Li, Y; Luo, F; Song, X; Wang, D; Wu, S; Zhang, N | 1 |
43 review(s) available for glycine and ixazomib
| Article | Year |
|---|---|
Clinical and marketed proteasome inhibitors for cancer treatment.
Topics: Boron Compounds; Boronic Acids; Bortezomib; Glycine; Humans; Lactones; Neoplasms; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrroles; Structure-Activity Relationship; Threonine | 2013 |
New approaches to management of multiple myeloma.
Topics: Adult; Age Factors; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Depsipeptides; Frail Elderly; Glycine; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Oligopeptides; Phosphorylcholine; Proteasome Inhibitors; Pyrazines; Quality of Life; Recurrence; Thalidomide; Treatment Outcome | 2014 |
[Proteasome inhibitor].
Topics: Boron Compounds; Boronic Acids; Bortezomib; Glycine; Humans; Molecular Targeted Therapy; Neoplasms; Proteasome Inhibitors; Pyrazines; Ubiquitin | 2014 |
The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma.
Topics: Animals; Boron Compounds; Drug Evaluation, Preclinical; Drugs, Investigational; Glycine; Humans; Multiple Myeloma; Proteasome Inhibitors | 2015 |
Ixazomib for the treatment of multiple myeloma.
Topics: Antineoplastic Agents; Boron Compounds; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Glycine; Humans; Multiple Myeloma; Proteasome Inhibitors | 2015 |
Lessons Learned From the Clinical Trials of Novel Biologics and Small Molecules in Lupus Nephritis.
Topics: Abatacept; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biological Products; Boron Compounds; Bortezomib; Clinical Trials as Topic; Drug Discovery; Glycine; Humans; Immunologic Factors; Immunosuppressive Agents; Infliximab; Isoxazoles; Leflunomide; Lupus Nephritis; Mycophenolic Acid; Off-Label Use; Oligonucleotides; Quinolones; Recombinant Fusion Proteins; Rituximab; Tacrolimus; Treatment Outcome | 2015 |
Oral ixazomib maintenance therapy in multiple myeloma.
Topics: Administration, Oral; Antineoplastic Agents; Boron Compounds; Glycine; Humans; Multiple Myeloma; Proteasome Inhibitors | 2016 |
Spotlight on ixazomib: potential in the treatment of multiple myeloma.
Topics: Animals; Antineoplastic Agents; Boron Compounds; Drug Approval; Drug Resistance, Neoplasm; Glycine; Humans; Multiple Myeloma; Proteasome Inhibitors; Survival Rate | 2016 |
Ixazomib: First Global Approval.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Clinical Trials as Topic; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Approval; Drug Evaluation, Preclinical; Glycine; Humans; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Binding | 2016 |
Safety of proteasome inhibitors for treatment of multiple myeloma.
Topics: Antineoplastic Agents; Boron Compounds; Bortezomib; Drug Resistance, Neoplasm; Glycine; Humans; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors | 2017 |
Magic year for multiple myeloma therapeutics: Key takeaways from the ASH 2015 annual meeting.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Boron Compounds; Congresses as Topic; Glycine; Humans; Hydrazines; Molecular Targeted Therapy; Multiple Myeloma; Proteasome Inhibitors; Protein Kinase Inhibitors; Signal Transduction; Thiadiazoles; Treatment Outcome; Triazoles | 2017 |
Management of adverse events induced by next-generation immunomodulatory drug and proteasome inhibitors in multiple myeloma.
Topics: Antineoplastic Agents; Boron Compounds; Dose-Response Relationship, Drug; Glycine; Humans; Immunologic Factors; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Survival Rate; Thalidomide | 2017 |
Proteasome Inhibitors as a Potential Cause of Heart Failure.
Topics: Antineoplastic Agents; Boron Compounds; Bortezomib; Clinical Trials as Topic; Drug Approval; Early Diagnosis; Glycine; Heart Failure; Humans; Meta-Analysis as Topic; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors | 2017 |
Proteasome inhibitor-induced gastrointestinal toxicity.
Topics: Antineoplastic Agents; Boron Compounds; Bortezomib; Clinical Trials as Topic; Gastrointestinal Diseases; Glycine; Humans; Oligopeptides; Proteasome Inhibitors | 2017 |
Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Dexamethasone; Glycine; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Lenalidomide; Multiple Myeloma; Oligopeptides; Panobinostat; Proteasome Inhibitors; Recurrence; Thalidomide | 2017 |
Ixazomib: A Review in Relapsed and/or Refractory Multiple Myeloma.
Topics: Antineoplastic Agents; Boron Compounds; Female; Glycine; Humans; Male; Multiple Myeloma | 2017 |
Safety of ixazomib for the treatment of multiple myeloma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Drug Administration Schedule; Drug Resistance, Neoplasm; Glycine; Humans; Multiple Myeloma; Protease Inhibitors; Recurrence; Survival Rate | 2017 |
Pooled analysis of the reports of carfilzomib/ixazomib combinations for relapsed/refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Drug Administration Schedule; Female; Glycine; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Prospective Studies; Proteasome Inhibitors; Recurrence; Survival Analysis; Thalidomide | 2018 |
The effect of novel therapies in high-molecular-risk multiple myeloma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boron Compounds; Disease-Free Survival; Glycine; Humans; Hydroxamic Acids; Indoles; Kaplan-Meier Estimate; Multiple Myeloma; Oligopeptides; Panobinostat; Prognosis | 2017 |
Pharmacokinetic drug evaluation of ixazomib citrate for the treatment of multiple myeloma.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Boron Compounds; Dexamethasone; Glycine; Half-Life; Humans; Lenalidomide; Multiple Myeloma; Protease Inhibitors; Salvage Therapy; Thalidomide; Tissue Distribution | 2018 |
Triplet vs. doublet drug regimens for managing multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Boron Compounds; Glycine; Histone Deacetylase Inhibitors; Humans; Multiple Myeloma; Oligopeptides; Stem Cell Transplantation; Thalidomide | 2018 |
Model-Informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor.
Topics: Animals; Biological Availability; Boron Compounds; Clinical Trials, Phase III as Topic; Drug Development; Glycine; Humans; Models, Theoretical; Multiple Myeloma; Proteasome Inhibitors | 2019 |
Ixazomib in the management of relapsed multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Clinical Trials as Topic; Dexamethasone; Disease Management; Glycine; Humans; Lenalidomide; Multiple Myeloma; Proteasome Inhibitors; Recurrence | 2018 |
Proteasome inhibitors for the treatment of multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Boron Compounds; Bortezomib; Glycine; Hematologic Diseases; Humans; Lactones; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Proteasome Inhibitors; Pyrroles | 2018 |
Ixazomib for Relapsed or Refractory Multiple Myeloma: Review from an Evidence Review Group on a NICE Single Technology Appraisal.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Cost-Benefit Analysis; Dexamethasone; Disease-Free Survival; Glycine; Humans; Lenalidomide; Models, Economic; Multiple Myeloma; Proteasome Inhibitors; Quality-Adjusted Life Years; Technology Assessment, Biomedical | 2018 |
Next-generation proteasome inhibitors for cancer therapy.
Topics: Antineoplastic Agents; Boron Compounds; Bortezomib; Drug Resistance, Neoplasm; Glycine; Humans; Neoplasms; Oligopeptides; Proteasome Inhibitors | 2018 |
Proteasome inhibitors: structure and function.
Topics: Antineoplastic Agents; Boron Compounds; Bortezomib; Glycine; Hematologic Neoplasms; Humans; Lymphoma, Mantle-Cell; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Structure-Activity Relationship | 2017 |
Novel Approaches for the Management of AL Amyloidosis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Boron Compounds; Glycine; Humans; Immunoglobulin Light-chain Amyloidosis; Magnetic Resonance Imaging; Prognosis; Thalidomide | 2018 |
Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor.
Topics: Administration, Oral; Antineoplastic Agents; Boron Compounds; Dose-Response Relationship, Drug; Glycine; Humans; Proteasome Inhibitors | 2019 |
Ixazomib: a novel drug for multiple myeloma.
Topics: Administration, Oral; Animals; Boron Compounds; Clinical Trials as Topic; Glycine; Humans; Multiple Myeloma; Protease Inhibitors | 2018 |
Ixazomib for the treatment of multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Glycine; Humans; Lenalidomide; Multiple Myeloma; Proteasome Inhibitors | 2018 |
Ixazomib - the first oral proteasome inhibitor.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Clinical Trials as Topic; Cost-Benefit Analysis; Drug Resistance, Neoplasm; Glycine; Humans; Molecular Targeted Therapy; Multiple Myeloma; Proteasome Inhibitors; Recurrence; Retreatment; Treatment Outcome | 2019 |
Ixazomib: an investigational drug for the treatment of lymphoproliferative disorders.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Boron Compounds; Dexamethasone; Drugs, Investigational; Glycine; Humans; Immunoglobulin Light-chain Amyloidosis; Lymphoproliferative Disorders; Multiple Myeloma; Protease Inhibitors; Waldenstrom Macroglobulinemia | 2019 |
Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases.
Topics: Animals; Antineoplastic Agents; Autoimmune Diseases; Boron Compounds; Bortezomib; Glycine; Hematologic Neoplasms; Humans; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors | 2019 |
Proteasome Inhibitors: Harnessing Proteostasis to Combat Disease.
Topics: Antineoplastic Agents; Boron Compounds; Bortezomib; Glycine; Humans; Lactones; Molecular Targeted Therapy; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Proteostasis; Pyrroles | 2020 |
Maintenance therapy and need for cessation studies in multiple myeloma: Focus on the future.
Topics: Adaptive Clinical Trials as Topic; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Glycine; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Neoplasm, Residual; Oligopeptides; Thalidomide; Transplantation, Autologous; Withholding Treatment | 2020 |
The Ubiquitin-Proteasome Pathway and Epigenetic Modifications in Cancer.
Topics: Acetylation; Boron Compounds; Bortezomib; DNA Modification Methylases; Enzyme Inhibitors; Epigenesis, Genetic; Glycine; Histone Acetyltransferases; Histone Deacetylases; Humans; Hydroxamic Acids; Methylation; Neoplasms; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Processing, Post-Translational; Signal Transduction; Terphenyl Compounds; Ubiquitin; Ubiquitination; Valproic Acid | 2021 |
Ixazomib-associated cardiovascular adverse events in multiple myeloma: a systematic review and meta-analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Glycine; Humans; Hypertension; Multiple Myeloma | 2022 |
Pharmacology differences among proteasome inhibitors: Implications for their use in clinical practice.
Topics: Animals; Antineoplastic Agents; Boron Compounds; Bortezomib; Drug Interactions; Glycine; Humans; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors | 2021 |
Merging the Versatile Functionalities of Boronic Acid with Peptides.
Topics: Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Drug Design; Enzyme Inhibitors; Glycine; Humans; Peptides; Protease Inhibitors | 2021 |
Efficacy and safety of ixazomib maintenance therapy for patients with multiple myeloma: a meta-analysis.
Topics: Antineoplastic Agents; Boron Compounds; Gastrointestinal Diseases; Glycine; Humans; Infections; Maintenance Chemotherapy; Multiple Myeloma; Progression-Free Survival; Thrombocytopenia | 2021 |
Efficacy of ixazomib-lenalidomide-dexamethasone in high-molecular-risk relapsed/refractory multiple myeloma - case series and literature review.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Glycine; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local | 2022 |
Efficacy of maintenance treatment in patients with multiple myeloma: a systematic review and network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Glycine; Humans; Lenalidomide; Multiple Myeloma; Network Meta-Analysis; Prednisone; Thalidomide | 2022 |
67 trial(s) available for glycine and ixazomib
| Article | Year |
|---|---|
Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma.
Topics: Administration, Oral; Adult; Aged; Area Under Curve; Boron Compounds; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Drugs, Investigational; Fatigue; Female; Glycine; Humans; Male; Middle Aged; Multiple Myeloma; Nausea; Neoplasm Recurrence, Local; Proteasome Inhibitors; Remission Induction; Thrombocytopenia; Treatment Outcome; Vomiting | 2014 |
Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients.
Topics: Administration, Oral; Aged; Aged, 80 and over; Area Under Curve; Boron Compounds; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Exanthema; Fatigue; Female; Glycine; Humans; Male; Middle Aged; Multiple Myeloma; Nausea; Neoplasm Recurrence, Local; Proteasome Inhibitors; Thrombocytopenia; Treatment Outcome | 2014 |
Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma.
Topics: Adult; Aged; Boron Compounds; Diarrhea; Female; Glycine; Humans; Lymphoma, Follicular; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Neutropenia; Peripheral Nervous System Diseases; Proteasome Inhibitors; Thrombocytopenia | 2014 |
Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Female; Follow-Up Studies; Glycine; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Proteasome Inhibitors; Safety; Survival Rate; Thalidomide | 2014 |
Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies.
Topics: Activating Transcription Factor 3; Adult; Aged; Boron Compounds; Cohort Studies; Dose-Response Relationship, Drug; Female; Glycine; Hematologic Neoplasms; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Proteasome Inhibitors; Treatment Outcome | 2015 |
Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Boron Compounds; Dexamethasone; Disease-Free Survival; Female; Glycine; Humans; Male; Middle Aged; Multiple Myeloma; Recurrence; Treatment Outcome | 2015 |
Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study.
Topics: Adult; Aged; Antineoplastic Agents; Asia; Boron Compounds; Dexamethasone; Female; Glycine; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide | 2015 |
The Effect of a High-Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma.
Topics: Aged; Aged, 80 and over; Area Under Curve; Biological Availability; Boron Compounds; Cross-Over Studies; Diet, High-Fat; Female; Food-Drug Interactions; Glycine; Humans; Intestinal Absorption; Lymphoma; Male; Meals; Middle Aged; Neoplasms; Proteasome Inhibitors | 2016 |
Exposure-safety-efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance study.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Boron Compounds; Disease Progression; Dose-Response Relationship, Drug; Female; Glycine; Humans; Logistic Models; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Protease Inhibitors | 2016 |
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Disease-Free Survival; Double-Blind Method; Exanthema; Glycine; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Proportional Hazards Models; Quality of Life; Thalidomide; Thrombocytopenia | 2016 |
Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Boron Compounds; Female; Glycine; Humans; Liver Diseases; Male; Middle Aged; Neoplasms; Proteasome Inhibitors; Young Adult | 2016 |
A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysis.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anemia; Blood Proteins; Boron Compounds; Drug Dosage Calculations; Female; Glycine; Humans; Kidney Failure, Chronic; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Renal Dialysis; Renal Insufficiency | 2016 |
Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Female; Glycine; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Survival Analysis; Treatment Outcome | 2016 |
Phase 1 study of ixazomib alone or combined with lenalidomide-dexamethasone in Japanese patients with relapsed/refractory multiple myeloma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asian People; Boron Compounds; Dexamethasone; Drug Administration Schedule; Female; Glycine; Humans; Lenalidomide; Leukopenia; Male; Multiple Myeloma; Proteasome Inhibitors; Recurrence; Salvage Therapy; Thalidomide; Thrombocytopenia | 2017 |
Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Eruptions; Follow-Up Studies; Glycine; Hematologic Diseases; Humans; Lenalidomide; Leukocyte Count; Male; Middle Aged; Multiple Myeloma; Nausea; Peripheral Nervous System Diseases; Platelet Count; Thalidomide; Vomiting | 2017 |
A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis.
Topics: Administration, Oral; Aged; Amyloidosis; Boron Compounds; Disease-Free Survival; Female; Follow-Up Studies; Glycine; Humans; Male; Middle Aged; Proteasome Inhibitors; Survival Rate | 2017 |
Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; China; Dexamethasone; Disease-Free Survival; Double-Blind Method; Female; Glycine; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Placebo Effect; Thalidomide | 2017 |
A Phase 1 Study to Assess the Relative Bioavailability of Two Capsule Formulations of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Biological Availability; Boron Compounds; Capsules; Chemistry, Pharmaceutical; Cross-Over Studies; Fatigue; Female; Glycine; Humans; Lymphoma; Male; Middle Aged; Nausea; Proteasome Inhibitors | 2018 |
Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Ana
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boron Compounds; Clarithromycin; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Female; Glycine; Humans; Ketoconazole; Male; Middle Aged; Models, Biological; Neoplasms; Proteasome Inhibitors; Rifampin | 2018 |
Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses.
Topics: Antineoplastic Agents; Boron Compounds; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Glycine; Humans; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Proteasome Inhibitors | 2017 |
A single center phase II study of ixazomib in patients with relapsed or refractory cutaneous or peripheral T-cell lymphomas.
Topics: Aged; Boron Compounds; Cell Line, Tumor; Female; GATA3 Transcription Factor; Glycine; Humans; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; NF-kappa B; Protease Inhibitors; Salvage Therapy; Tumor Cells, Cultured | 2017 |
A phase I study to assess the mass balance, excretion, and pharmacokinetics of [
Topics: Administration, Oral; Aged; Boron Compounds; Carbon Radioisotopes; Feces; Female; Glycine; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Proteasome Inhibitors; Radioactivity; Treatment Outcome; Urine | 2018 |
Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Chromosome Aberrations; Dexamethasone; Disease-Free Survival; Double-Blind Method; Drug Resistance, Neoplasm; Female; Glycine; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Outcome Assessment, Health Care; Proportional Hazards Models; Thalidomide | 2017 |
The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study pro
Topics: Antineoplastic Agents; Boron Compounds; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Female; Glycine; Humans; Maintenance Chemotherapy; Male; Multicenter Studies as Topic; Multiple Myeloma; Neoplasm, Residual; Progression-Free Survival; Proteasome Inhibitors; Quality of Life; Randomized Controlled Trials as Topic; Recurrence; Salvage Therapy; Stem Cell Transplantation; Time Factors; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; United Kingdom | 2018 |
Healthcare resource utilization with ixazomib or placebo plus lenalidomide-dexamethasone in the randomized, double-blind, phase 3 TOURMALINE-MM1 study in relapsed/refractory multiple myeloma.
Topics: Absenteeism; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Disease Progression; Double-Blind Method; Female; Glycine; Health Resources; Health Services; Hospitalization; Humans; Lenalidomide; Male; Middle Aged; Models, Econometric; Multiple Myeloma; Time Factors | 2018 |
Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Glycine; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Treatment Outcome | 2018 |
Biotransformation of [
Topics: Administration, Oral; Antineoplastic Agents; Area Under Curve; Biotransformation; Boron Compounds; Carbon Radioisotopes; Feces; Female; Glycine; Humans; Male; Metabolome; Neoplasms | 2018 |
Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Austria; Boron Compounds; Bortezomib; Carboplatin; Dose-Response Relationship, Drug; Female; Glycine; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Progression-Free Survival; Quality of Life; Triple Negative Breast Neoplasms | 2018 |
Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed/refractory multiple myeloma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Female; Glycine; Humans; Male; Middle Aged; Multiple Myeloma; Recurrence; Survival Rate | 2019 |
All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Australia; Boron Compounds; Contraindications, Procedure; Cyclophosphamide; Dexamethasone; Disease Progression; Eligibility Determination; Europe; Female; Glycine; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Progression-Free Survival; Time Factors; United States | 2019 |
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial.
Topics: Administration, Oral; Antineoplastic Agents; Boron Compounds; Disease Progression; Double-Blind Method; Female; Glycine; Humans; Male; Middle Aged; Multiple Myeloma; Stem Cell Transplantation; Time Factors; Transplantation, Autologous; Treatment Outcome | 2019 |
Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Female; Follow-Up Studies; Glycine; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Prognosis; Survival Rate | 2019 |
Management of Gastrointestinal Toxicities From Ixazomib: Tips to Curb Nausea, Vomiting, Diarrhea, and Constipation.
Topics: Antineoplastic Agents; Boron Compounds; Constipation; Diarrhea; Glycine; Humans; Multiple Myeloma; Nausea; Proteasome Inhibitors; Vomiting | 2019 |
Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Female; Glycine; Humans; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Quality of Life; Treatment Outcome | 2019 |
A Phase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Glycine; Humans; Leukemia, Myeloid, Acute; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Patient Safety; Remission Induction; Salvage Therapy; Treatment Outcome | 2019 |
Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Female; Glycine; Humans; Induction Chemotherapy; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Progression-Free Survival; Survival Rate; Thalidomide | 2019 |
Quality of life is maintained with ixazomib maintenance in post-transplant newly diagnosed multiple myeloma: The TOURMALINE-MM3 trial.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Combined Modality Therapy; Female; Glycine; Hematopoietic Stem Cell Transplantation; Humans; Maintenance Chemotherapy; Male; Medication Adherence; Middle Aged; Multiple Myeloma; Patient Reported Outcome Measures; Quality of Life; Treatment Outcome | 2020 |
Phase I Study of Selinexor, Ixazomib, and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Female; Glycine; Humans; Hydrazines; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Triazoles | 2020 |
Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies.
Topics: Adult; Aged; Angiogenesis Inhibitors; Boron Compounds; Glycine; Humans; Indazoles; Kaplan-Meier Estimate; Middle Aged; Mutation; Neoplasms; Progression-Free Survival; Pyrimidines; Sulfonamides; Treatment Outcome; Tumor Suppressor Protein p53; Vorinostat; Young Adult | 2020 |
Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Disease-Free Survival; Female; Glycine; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Survival Rate | 2020 |
Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Boron Compounds; Combined Modality Therapy; Female; Glycine; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Postoperative Care; Treatment Outcome; Young Adult | 2020 |
Clinical benefit of ixazomib plus lenalidomide-dexamethasone in myeloma patients with non-canonical NF-κB pathway activation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boron Compounds; Chromosome Aberrations; Dexamethasone; Gene Expression Regulation, Neoplastic; Glycine; Humans; Lenalidomide; Multiple Myeloma; Mutation; NF-kappa B; Prognosis; Progression-Free Survival; Signal Transduction; Transcriptome; Treatment Outcome | 2020 |
Ixazomib for Treatment of Refractory Chronic Graft-versus-Host Disease: A Chronic GVHD Consortium Phase II Trial.
Topics: Boron Compounds; Chronic Disease; Glycine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans | 2020 |
Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Boron Compounds; Disease-Free Survival; Female; Follow-Up Studies; Glycine; Humans; Male; Middle Aged; Multiple Myeloma; Silicates; Stem Cell Transplantation; Survival Rate | 2020 |
Ixazomib for Chronic Graft-versus-Host Disease Prophylaxis following Allogeneic Hematopoietic Cell Transplantation.
Topics: Boron Compounds; Chronic Disease; Glycine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Tacrolimus; Transplantation Conditioning | 2020 |
Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Chromosome Aberrations; Dexamethasone; Drug Resistance, Neoplasm; Female; Flow Cytometry; Glycine; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm, Residual; Progression-Free Survival; Treatment Outcome | 2021 |
Prospective phase 2 trial of ixazomib after nonmyeloablative haploidentical peripheral blood stem cell transplant.
Topics: Adult; Aged; Boron Compounds; Glycine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prospective Studies | 2020 |
Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up.
Topics: Boron Compounds; Dexamethasone; Follow-Up Studies; Glycine; Humans; Myeloid Differentiation Factor 88; Prospective Studies; Rituximab; Waldenstrom Macroglobulinemia | 2020 |
Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial: a multi-center study.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Administration Schedule; Female; Glycine; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Peripheral Nervous System Diseases; Remission Induction; Survival Analysis; Thalidomide; Treatment Outcome | 2020 |
The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a prote
Topics: Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Clinical Trials, Phase II as Topic; Cyclophosphamide; Dexamethasone; Glycine; Humans; Lenalidomide; Multicenter Studies as Topic; Multiple Myeloma; Proteasome Inhibitors; Randomized Controlled Trials as Topic; Thalidomide | 2020 |
Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial.
Topics: Aged; Antineoplastic Agents; Boron Compounds; Double-Blind Method; Female; Glycine; Humans; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Placebos; Progression-Free Survival; Proteasome Inhibitors; Stem Cell Transplantation; Treatment Outcome | 2020 |
Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-1
Topics: Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Dexamethasone; Glycine; Hematopoietic Stem Cell Transplantation; Humans; Multiple Myeloma; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2020 |
Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Disease-Free Survival; Double-Blind Method; Female; Follow-Up Studies; Glycine; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Survival Rate | 2021 |
Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma: The Hovon 143 Study.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Female; Follow-Up Studies; Frail Elderly; Glycine; Humans; Male; Multiple Myeloma; Prognosis; Prospective Studies; Quality of Life; Survival Rate | 2021 |
A phase II trial of continuous ixazomib, thalidomide and dexamethasone for relapsed and/or refractory multiple myeloma: the Australasian Myeloma Research Consortium (AMaRC) 16-02 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Australia; Boron Compounds; Dexamethasone; Female; Glycine; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Progression-Free Survival; Thalidomide | 2021 |
A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Cyclophosphamide; Dexamethasone; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Glycine; Humans; Immunoglobulin Light-chain Amyloidosis; Lenalidomide; Male; Middle Aged; Neoplasm Recurrence, Local; Physicians; Prognosis; Salvage Therapy; Survival Rate; Thalidomide | 2022 |
A phase i study of ixazomib and erlotinib in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Glycine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; NF-kappa B | 2022 |
A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Drug Resistance, Neoplasm; Female; Glycine; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Proteasome Inhibitors; Thalidomide | 2021 |
A phase 2, open-label, multicenter study of ixazomib plus lenalidomide and dexamethasone in adult Japanese patients with relapsed and/or refractory multiple myeloma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Glycine; Humans; Japan; Lenalidomide; Multiple Myeloma | 2022 |
Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Female; Glycine; Humans; Induction Chemotherapy; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Treatment Outcome | 2021 |
Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Disease-Free Survival; Female; Glycine; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Progression-Free Survival; Proteasome Inhibitors; Thalidomide | 2022 |
All-oral triplet combination of ixazomib, lenalidomide, and dexamethasone in newly diagnosed transplant-eligible multiple myeloma patients: final results of the phase II IFM 2013-06 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Glycine; Humans; Lenalidomide; Multiple Myeloma | 2022 |
Ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory myeloma: MUKeight phase II randomised controlled trial results.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Cyclophosphamide; Dexamethasone; Glycine; Humans; Multiple Myeloma | 2022 |
A phase 1/2 study of ixazomib in place of bortezomib or carfilzomib in a subsequent line of therapy for patients with multiple myeloma refractory to their last bortezomib or carfilzomib combination regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Dexamethasone; Glycine; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides | 2022 |
Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis.
Topics: Aged; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Glycine; Humans; Male; Multiple Myeloma; Proteasome Inhibitors | 2022 |
Phase 1/2 study of ixazomib with cyclophosphamide and dexamethasone in newly diagnosed AL amyloidosis.
Topics: Boron Compounds; Cyclophosphamide; Dexamethasone; Glycine; Humans; Immunoglobulin Light-chain Amyloidosis | 2022 |
Ixazomib for Desensitization (IXADES) in Highly Sensitized Kidney Transplant Candidates: A Phase II Clinical Trial.
Topics: Boron Compounds; Glycine; Humans; Kidney Transplantation; Multiple Myeloma | 2023 |
133 other study(ies) available for glycine and ixazomib
| Article | Year |
|---|---|
Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer.
Topics: Animals; Boron Compounds; Boronic Acids; Bortezomib; Cysteine Proteinase Inhibitors; Drug Screening Assays, Antitumor; Female; Glycine; HCT116 Cells; HT29 Cells; Humans; Lymphoma; Mice; Mice, SCID; Neoplasms; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Xenograft Model Antitumor Assays | 2010 |
In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Apoptosis; Biological Availability; Blotting, Western; Boron Compounds; Boronic Acids; Bortezomib; Caspase 3; Caspase 8; Caspase 9; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dexamethasone; Drug Synergism; Enzyme Activation; Glycine; Humans; Lenalidomide; Mice; Mice, SCID; Multiple Myeloma; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Thalidomide; Xenograft Model Antitumor Assays | 2011 |
Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies.
Topics: Animals; Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Cell Line, Tumor; Glycine; Humans; Lymphoma, B-Cell; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, SCID; Mice, Transgenic; Neoplasms, Plasma Cell; Osteolysis; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Xenograft Model Antitumor Assays | 2011 |
Drugs: More shots on target.
Topics: Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Resistance, Neoplasm; Glycine; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Oligopeptides; Protease Inhibitors; Pyrazines; Survival Rate; Thalidomide; Threonine | 2011 |
Next-generation proteasome blockers promise safer cancer therapy.
Topics: Antineoplastic Agents; Boron Compounds; Clinical Trials as Topic; Cysteine Proteinase Inhibitors; Drug Approval; Drug Industry; Glycine; Humans; Neoplasms; Oligopeptides; Proteasome Inhibitors | 2012 |
Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells.
Topics: Animals; Antineoplastic Agents; Boron Compounds; Cell Death; Cell Line, Tumor; Cell Movement; Cell Survival; Cluster Analysis; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Glycine; Humans; Imidazoles; Mice; MicroRNAs; Multiple Myeloma; Proto-Oncogene Proteins c-pim-1; Pyridazines; Signal Transduction; Xenograft Model Antitumor Assays | 2012 |
[Molecular targeting agents for multiple myeloma].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Glycine; Histone Deacetylases; Humans; Immunologic Factors; Lactones; Lenalidomide; Molecular Targeted Therapy; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Pyrazines; Pyrroles; Thalidomide | 2012 |
MLN2238, a proteasome inhibitor, induces caspase-dependent cell death, cell cycle arrest, and potentiates the cytotoxic activity of chemotherapy agents in rituximab-chemotherapy-sensitive or rituximab-chemotherapy-resistant B-cell lymphoma preclinical mod
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Apoptosis; B-Lymphocytes; Boron Compounds; Caspases; Cell Cycle; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Glycine; Humans; Proteasome Inhibitors; Rituximab; Time Factors | 2013 |
Ultra high performance liquid chromatography coupled with high resolution quantitation mass spectrometry method development and validation for determining genotoxic 2,5-dichlorobenzoyl chloride in MLN9708 drug substance.
Topics: Boron Compounds; Carbon Dioxide; Chlorides; Chlorobenzoates; Chromatography, High Pressure Liquid; Glycine; Hydrolysis; Limit of Detection; Tandem Mass Spectrometry; United States; United States Food and Drug Administration | 2014 |
The investigational agent MLN2238 induces apoptosis and is cytotoxic to CLL cells in vitro, as a single agent and in combination with other drugs.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boron Compounds; Caspase 3; Caspase 9; Cell Death; Cell Survival; Dexamethasone; Drug Synergism; Enzyme Activation; Glycine; Gossypol; Humans; Intracellular Membranes; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Mitochondria; Neoplasm Staging; Permeability; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Vidarabine | 2014 |
Preclinical activity of the oral proteasome inhibitor MLN9708 in Myeloma bone disease.
Topics: Animals; Antineoplastic Agents; Bone Resorption; Boron Compounds; Cell Line; Disease Models, Animal; Glycine; Humans; Immunoblotting; Mesenchymal Stem Cells; Mice; Mice, Inbred NOD; Mice, SCID; Multiple Myeloma; Osteoclasts; Proteasome Inhibitors; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction | 2014 |
MLN2238 synergizes BH3 mimetic ABT-263 in castration-resistant prostate cancer cells by induction of NOXA.
Topics: Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; BH3 Interacting Domain Death Agonist Protein; Boron Compounds; Cell Line, Tumor; Cell Survival; Drug Synergism; Glycine; Humans; Immunoblotting; Immunoprecipitation; Male; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering; Sulfonamides; Transfection | 2014 |
Oral therapy for multiple myeloma: ixazomib arriving soon.
Topics: Boron Compounds; Drugs, Investigational; Female; Glycine; Humans; Male; Multiple Myeloma; Proteasome Inhibitors | 2014 |
Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Body Surface Area; Boron Compounds; Clinical Trials, Phase I as Topic; Computer Simulation; Dose-Response Relationship, Drug; Feasibility Studies; Glycine; Humans; Injections, Intravenous; Lymphoma; Metabolic Clearance Rate; Middle Aged; Models, Biological; Multiple Myeloma; Protease Inhibitors; Young Adult | 2015 |
An oral proteasome inhibitor for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Female; Glycine; Humans; Male; Multiple Myeloma; Proteasome Inhibitors | 2014 |
Therapeutic landscape of carfilzomib and other modulators of the ubiquitin-proteasome pathway.
Topics: Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Cell Line, Tumor; Clinical Trials as Topic; Glycine; Hematologic Neoplasms; Humans; Neoplasms; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Signal Transduction; Ubiquitin | 2015 |
Aurora A Kinase Inhibition Selectively Synergizes with Histone Deacetylase Inhibitor through Cytokinesis Failure in T-cell Lymphoma.
Topics: Aminopterin; Animals; Aurora Kinase A; Azepines; Boron Compounds; Cell Cycle; Cell Line, Tumor; Centrosome; Cytokinesis; Depsipeptides; Drug Synergism; Glycine; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Inhibitory Concentration 50; Kaplan-Meier Estimate; Lymphoma, T-Cell; Mice; Mice, SCID; Mitosis; Neoplasm Transplantation; Protein Kinase Inhibitors; Pyrimidines; Spindle Apparatus; Xenograft Model Antitumor Assays | 2015 |
Calcineurin Inhibitor Minimization With Ixazomib, an Investigational Proteasome Inhibitor, for the Prevention of Antibody Mediated Rejection in a Preclinical Model.
Topics: Acute Disease; Animals; B-Lymphocytes; Biomarkers; Boron Compounds; Calcineurin Inhibitors; Cyclosporine; Disease Models, Animal; Drug Therapy, Combination; Gene Expression Regulation; Glycine; Graft Rejection; Graft Survival; Immunity, Humoral; Immunosuppressive Agents; Isoantibodies; Kidney; Kidney Transplantation; Male; Proteasome Inhibitors; Rats, Inbred BN; Rats, Inbred Lew; Signal Transduction; T-Lymphocytes | 2015 |
Integrated nonclinical and clinical risk assessment of the investigational proteasome inhibitor ixazomib on the QTc interval in cancer patients.
Topics: Animals; Boron Compounds; Clinical Trials, Phase I as Topic; Dogs; Electrocardiography; Ether-A-Go-Go Potassium Channels; Female; Glycine; HEK293 Cells; Humans; Male; Neoplasms; Proteasome Inhibitors; Risk Assessment | 2015 |
Selective Toxicity of Investigational Ixazomib for Human Leukemia Cells Expressing Mutant Cytoplasmic NPM1: Role of Reactive Oxygen Species.
Topics: Antineoplastic Agents; Apoptosis; Boron Compounds; Cell Line, Tumor; Cell Survival; Cytoplasm; Flow Cytometry; Gene Expression Regulation, Leukemic; Glutathione; Glycine; Histone Deacetylase Inhibitors; Humans; Immunophenotyping; Leukemia, Myeloid, Acute; Mutation; Nuclear Proteins; Nucleophosmin; Oxidation-Reduction; Protein Transport; Reactive Oxygen Species; Superoxides | 2016 |
Multiple Myeloma Gets Three New Drugs.
Topics: Administration, Oral; ADP-ribosyl Cyclase 1; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Clinical Trials, Phase III as Topic; Glycine; Humans; Membrane Glycoproteins; Multiple Myeloma; Treatment Outcome | 2016 |
Comparison of antiproliferative and apoptotic effects of a novel proteasome inhibitor MLN2238 with bortezomib on K562 chronic myeloid leukemia cells.
Topics: Apoptosis; Boron Compounds; Bortezomib; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Glycine; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2016 |
KRAS Genotype Correlates with Proteasome Inhibitor Ixazomib Activity in Preclinical In Vivo Models of Colon and Non-Small Cell Lung Cancer: Potential Role of Tumor Metabolism.
Topics: Amino Acids; Animals; Antineoplastic Agents; Boron Compounds; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Drug Resistance, Neoplasm; Fatty Acids; Glucose Transporter Type 4; Glycine; HCT116 Cells; Humans; Lung Neoplasms; Metabolome; Mice; Oxidation-Reduction; Proteasome Inhibitors; Proto-Oncogene Proteins p21(ras); Xenograft Model Antitumor Assays | 2015 |
FDA approves three different multiple myeloma drugs in one month.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Boron Compounds; Drug Approval; Drug Industry; Glycine; Humans; Multiple Myeloma; United States; United States Food and Drug Administration | 2016 |
Proteasomal Inhibition by Ixazomib Induces CHK1 and MYC-Dependent Cell Death in T-cell and Hodgkin Lymphoma.
Topics: Animals; Apoptosis; Biomarkers, Tumor; Blotting, Western; Boron Compounds; Cell Proliferation; Checkpoint Kinase 1; Chromatin Immunoprecipitation; Gene Expression Profiling; Glycine; Hodgkin Disease; Humans; Lymphoma, T-Cell; Mice; Mice, SCID; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-myc; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.
Topics: Aged; Animals; Antineoplastic Agents; Apoptosis; Boron Compounds; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Female; Glycine; Humans; Male; Mice; Middle Aged; Multiple Myeloma; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Thalidomide; Xenograft Model Antitumor Assays | 2016 |
Ixazomib for multiple myeloma.
Topics: Boron Compounds; Clinical Trials as Topic; Disease-Free Survival; Glycine; Humans; Multiple Myeloma | 2016 |
Increased protein processing gene signature in HDACi-resistant cells predicts response to proteasome inhibitors.
Topics: Animals; Antineoplastic Agents; Boron Compounds; Bortezomib; Drug Resistance, Neoplasm; Gene Expression Profiling; Glycine; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lymphoma, Large B-Cell, Diffuse; Male; Mice, SCID; Prognosis; Proteasome Inhibitors; U937 Cells; Vorinostat; Xenograft Model Antitumor Assays | 2017 |
Three new drugs for multiple myeloma.
Topics: ADP-ribosyl Cyclase 1; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boron Compounds; Disease-Free Survival; Glycine; Humans; Membrane Glycoproteins; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Signaling Lymphocytic Activation Molecule Family; Treatment Outcome | 2016 |
Next-generation proteasome inhibitor MLN9708 sensitizes breast cancer cells to doxorubicin-induced apoptosis.
Topics: Autophagy; Boron Compounds; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Dual Specificity Phosphatase 1; Female; Gene Expression Regulation, Neoplastic; Glycine; Humans; MAP Kinase Signaling System; MCF-7 Cells; Phosphorylation; Proteasome Inhibitors | 2016 |
Bortezomib and ixazomib protect firefly luciferase from degradation and can flaw respective reporter gene assays.
Topics: Boron Compounds; Bortezomib; Cell Line, Tumor; Cytochrome P-450 CYP3A; Genes, Reporter; Glycine; Humans; Luciferases, Firefly; Pregnane X Receptor; Proteolysis; Receptors, Steroid | 2016 |
Multiple myeloma--translation of trial results into reality.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boron Compounds; Bortezomib; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Cyclic N-Oxides; Drug Approval; Drug Discovery; Glycine; Humans; Indolizines; Lactones; Lenalidomide; Multiple Myeloma; Oligopeptides; Practice Guidelines as Topic; Pyridinium Compounds; Pyrroles; Thalidomide | 2016 |
The inhibition mechanism of human 20S proteasomes enables next-generation inhibitor design.
Topics: Antineoplastic Agents; Biocatalysis; Boron Compounds; Boronic Acids; Bortezomib; Catalytic Domain; Crystallography, X-Ray; Drug Design; Glycine; Humans; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Conformation; Threonine | 2016 |
Activation of Chymotrypsin-Like Activity of the Proteasome during Ischemia Induces Myocardial Dysfunction and Death.
Topics: Adenosine Triphosphate; Animals; Boron Compounds; Caspase 3; Cell Death; Chymotrypsin; Dose-Response Relationship, Drug; Enzyme Activation; Glycine; Heart; Hemodynamics; Male; Myocardial Ischemia; Myocardium; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Rats; Rats, Sprague-Dawley; Ryanodine Receptor Calcium Release Channel | 2016 |
Recent Data Supporting Novel Management Strategies for Patients With Multiple Myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Cyclophosphamide; Dexamethasone; Glycine; Humans; Multiple Myeloma; Stem Cell Transplantation; Treatment Outcome | 2016 |
The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Boron Compounds; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Female; Glycine; Humans; Interferon alpha-2; Interferon-alpha; Melanoma; Mice, Inbred BALB C; Mice, Nude; Mutation; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins B-raf; Recombinant Proteins; Skin Neoplasms; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Ixazomib cardiotoxicity: A possible class effect of proteasome inhibitors.
Topics: Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Boron Compounds; Cardiotoxicity; Echocardiography; Glycine; Heart Failure; Humans; Magnetic Resonance Imaging; Male; Multiple Myeloma; Protease Inhibitors | 2017 |
Post-Transplantation Cyclophosphamide and Ixazomib Combination Rescues Mice Subjected to Experimental Graft-versus-Host Disease and Is Superior to Either Agent Alone.
Topics: Animals; Bone Marrow Transplantation; Boron Compounds; Cyclophosphamide; Cytokines; Drug Administration Schedule; Drug Evaluation, Preclinical; Drug Synergism; Drug Therapy, Combination; Female; Glycine; Graft vs Host Disease; Intestine, Small; Lymphocyte Depletion; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Transgenic; Proteasome Inhibitors; Radiation Chimera; T-Lymphocytes | 2017 |
Ixazomib suppresses human dendritic cell and modulates murine graft-versus-host disease in a schedule-dependent fashion.
Topics: Animals; Boron Compounds; Cell Differentiation; Cytokines; Dendritic Cells; Disease Models, Animal; Female; Glycine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunomodulation; Mice; Protease Inhibitors; T-Lymphocytes; Transplantation, Homologous | 2017 |
Ixazomib-induced thrombotic microangiopathy.
Topics: Aged; Boron Compounds; Female; Glycine; Humans; Multiple Myeloma; Thrombotic Microangiopathies | 2017 |
Expression level is a key determinant of E2F1-mediated cell fate.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Apoptotic Protease-Activating Factor 1; Bcl-2-Like Protein 11; Boron Compounds; Cell Cycle Checkpoints; Cell Line, Tumor; E2F1 Transcription Factor; Glycine; HCT116 Cells; Histones; Humans; Proto-Oncogene Proteins; Tamoxifen; Time-Lapse Imaging | 2017 |
A New Perspective for Osteosarcoma Therapy: Proteasome Inhibition by MLN9708/2238 Successfully Induces Apoptosis and Cell Cycle Arrest and Attenuates the Invasion Ability of Osteosarcoma Cells in Vitro.
Topics: Apoptosis; bcl-2-Associated X Protein; Boron Compounds; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Membrane Permeability; Cell Movement; Cyclin-Dependent Kinase Inhibitor p21; Down-Regulation; E2F1 Transcription Factor; G2 Phase Cell Cycle Checkpoints; Glycine; Humans; M Phase Cell Cycle Checkpoints; Mitochondria; Osteosarcoma; Proteasome Endopeptidase Complex; Proto-Oncogene Proteins c-bcl-2; Tumor Suppressor Protein p53; Up-Regulation | 2017 |
Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Boron Compounds; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Drug Labeling; Female; Glycine; Humans; Male; Middle Aged; Models, Biological; Proteasome Inhibitors; Young Adult | 2017 |
The evaluation of the anti-cancer activity of ixazomib on Caco2 colon solid tumor cells, comparison with bortezomib.
Topics: Adenocarcinoma; Antineoplastic Agents; Boron Compounds; Bortezomib; Caco-2 Cells; Caspase 3; Colonic Neoplasms; Drug Evaluation, Preclinical; Glycine; Humans; Membrane Potential, Mitochondrial; NF-kappa B p50 Subunit; Proto-Oncogene Proteins c-myc | 2017 |
Ritonavir and ixazomib kill bladder cancer cells by causing ubiquitinated protein accumulation.
Topics: Acetylation; Antineoplastic Agents; Apoptosis; Boron Compounds; Cell Line, Tumor; Cyclin D1; Cyclin-Dependent Kinase 4; Drug Synergism; Endoplasmic Reticulum Stress; Glycine; Humans; Proteasome Inhibitors; Ritonavir; Ubiquitinated Proteins; Ubiquitination; Urinary Bladder Neoplasms | 2017 |
Ixazomib enhances parathyroid hormone-induced β-catenin/T-cell factor signaling by dissociating β-catenin from the parathyroid hormone receptor.
Topics: Animals; beta Catenin; Bone and Bones; Boron Compounds; Cell Culture Techniques; Cyclic AMP; Glycine; Humans; Mice; Mice, Inbred C57BL; Osteoblasts; Parathyroid Hormone; Phosphorylation; Proteasome Inhibitors; Receptor, Parathyroid Hormone, Type 1; Signal Transduction; T-Lymphocytes; TCF Transcription Factors | 2017 |
The activity and safety of novel proteasome inhibitors strategies (single, doublet and triplet) for relapsed/refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Glycine; Humans; Lactones; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Proteasome Inhibitors; Pyrroles; Retrospective Studies | 2018 |
Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies.
Topics: Activating Transcription Factor 4; Animals; Antineoplastic Agents; Apoptosis; Azacitidine; Boron Compounds; Cell Line, Tumor; Cell Survival; Drug Screening Assays, Antitumor; Drug Synergism; G1 Phase Cell Cycle Checkpoints; Glycine; Hematologic Neoplasms; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Mice; Mice, SCID; Pyridines; Pyrimidines; Transcription Factor CHOP; Transplantation, Heterologous | 2018 |
Therapy sequencing strategies in multiple myeloma: who, what and why?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Glycine; Humans; Hydroxamic Acids; Indoles; Multiple Myeloma; Oligopeptides; Panobinostat; Thalidomide | 2018 |
Preclinical evaluation of antitumor activity of the proteasome inhibitor MLN2238 (ixazomib) in hepatocellular carcinoma cells.
Topics: Animals; Antineoplastic Agents; Boron Compounds; Carcinoma, Hepatocellular; Glycine; Humans; Liver Neoplasms; Mice; Proteasome Inhibitors | 2018 |
Ixazomib-induced cutaneous necrotizing vasculitis.
Topics: Aged, 80 and over; Boron Compounds; Glycine; Humans; Male; Proteasome Inhibitors; Vasculitis | 2018 |
Ixazomib, an oral proteasome inhibitor, induces rapid mobilization of hematopoietic progenitor cells in mice.
Topics: Administration, Oral; Animals; Boron Compounds; Glycine; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Mice; Mice, Inbred BALB C; Proteasome Inhibitors; Time Factors | 2018 |
The GSK3 Signaling Axis Regulates Adaptive Glutamine Metabolism in Lung Squamous Cell Carcinoma.
Topics: Animals; Benzeneacetamides; Boron Compounds; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glutamine; Glycine; Glycogen Synthase Kinase 3; Glycolysis; Humans; Ki-67 Antigen; Lung Neoplasms; Mice; Neoplasm Transplantation; Signal Transduction; Thiadiazoles | 2018 |
Myocyte-Damaging Effects and Binding Kinetics of Boronic Acid and Epoxyketone Proteasomal-Targeted Drugs.
Topics: Animals; Animals, Newborn; Boron Compounds; Boronic Acids; Bortezomib; Cardiotoxicity; Cell Survival; Dose-Response Relationship, Drug; Epoxy Compounds; Glycine; Humans; K562 Cells; Ketones; Kinetics; Myocytes, Cardiac; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Binding; Rats, Sprague-Dawley; Threonine | 2018 |
Pre-clinical evaluation of proteasome inhibitors for canine and human osteosarcoma.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Bone Neoplasms; Boron Compounds; Boronic Acids; Bortezomib; Carboplatin; Cell Line, Tumor; Dog Diseases; Dogs; Doxorubicin; Glycine; Humans; Oligopeptides; Osteosarcoma; Proteasome Inhibitors; Sulfonamides; Threonine | 2018 |
Spectrum and functional validation of PSMB5 mutations in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boron Compounds; Bortezomib; Cohort Studies; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Glycine; Humans; Male; Middle Aged; Multiple Myeloma; Mutation; Neoplasm Recurrence, Local; Oligopeptides; Prognosis; Proteasome Endopeptidase Complex; Survival Rate | 2019 |
FOXM1 contributes to treatment failure in acute myeloid leukemia.
Topics: Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Cell Line, Tumor; Cell Nucleus; Drug Resistance, Neoplasm; Female; Forkhead Box Protein M1; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Glycine; Humans; Leukemia, Myeloid, Acute; Male; Mice; Middle Aged; Mutation; Nuclear Proteins; Nucleophosmin; Primary Cell Culture; Proteasome Inhibitors; Retrospective Studies; Treatment Failure; Xenograft Model Antitumor Assays | 2018 |
Small Bowel Ulcers From Cryocrystalglobulinemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Cryoglobulinemia; Cryoglobulins; Crystallization; Cyclophosphamide; Dexamethasone; Double-Balloon Enteroscopy; Duodenal Ulcer; Glycine; Humans; Jejunal Diseases; Male; Ulcer; Vasculitis | 2020 |
Non-invasive imaging of disrupted protein homeostasis induced by proteasome inhibitor treatment using chemical exchange saturation transfer MRI.
Topics: Amides; Amines; Animals; Apoptosis; Boron Compounds; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Diffusion Magnetic Resonance Imaging; Dose-Response Relationship, Drug; Female; Glycine; Humans; Image Interpretation, Computer-Assisted; Magnetic Resonance Imaging; Mice, Nude; Proteasome Inhibitors; Proteostasis; Tumor Burden; Xenograft Model Antitumor Assays | 2018 |
Ixazomib promotes CHOP-dependent DR5 induction and apoptosis in colorectal cancer cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boron Compounds; Cell Line, Tumor; Colorectal Neoplasms; Cyclophosphamide; Doxorubicin; Glycine; Humans; Prednisone; Receptors, TNF-Related Apoptosis-Inducing Ligand; Transfection; Vincristine | 2019 |
Targeted Therapy for EBV-Associated B-cell Neoplasms.
Topics: Antineoplastic Agents; Boron Compounds; Cell Line, Tumor; Epstein-Barr Virus Infections; G2 Phase Cell Cycle Checkpoints; Glycine; Humans; Lymphoma, B-Cell; M Phase Cell Cycle Checkpoints; Molecular Targeted Therapy; NF-kappa B; NF-KappaB Inhibitor alpha; Phosphorylation; Protease Inhibitors; Proteasome Endopeptidase Complex; Up-Regulation | 2019 |
Oral proteasome inhibitor maintenance for multiple myeloma.
Topics: Boron Compounds; Double-Blind Method; Glycine; Humans; Multiple Myeloma; Proteasome Inhibitors; Silicates; Stem Cell Transplantation | 2019 |
[Ixazomib].
Topics: Boron Compounds; Glycine; Humans; Multiple Myeloma; Proteasome Inhibitors | 2016 |
Real World Efficacy and Safety Results of Ixazomib Lenalidomide and Dexamethasone Combination in Relapsed/Refractory Multiple Myeloma: Data Collected from the Hungarian Ixazomib Named Patient Program.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Glycine; Humans; Hungary; Lenalidomide; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Safety; Salvage Therapy; Survival Rate | 2019 |
Real-world treatment patterns, resource use and cost burden of multiple myeloma in Portugal.
Topics: Age Factors; Aged; Antineoplastic Agents; Boron Compounds; Bortezomib; Drug Costs; Female; Glycine; Health Care Costs; Health Resources; Hospitalization; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Portugal; Practice Patterns, Physicians'; Progression-Free Survival; Proteasome Inhibitors; Stem Cell Transplantation; Survival Rate; Thalidomide | 2019 |
Ubiquitination of MAP1LC3B by pVHL is associated with autophagy and cell death in renal cell carcinoma.
Topics: Animals; Autophagy; Boron Compounds; Carcinoma, Renal Cell; Cell Death; Female; Glycine; HeLa Cells; Humans; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Microtubule-Associated Proteins; Transfection; Tumor Burden; Ubiquitination; Von Hippel-Lindau Tumor Suppressor Protein; Xenograft Model Antitumor Assays | 2019 |
Novel cell line models to study mechanisms and overcoming strategies of proteasome inhibitor resistance in multiple myeloma.
Topics: A549 Cells; Amino Acid Substitution; Antineoplastic Agents; Boron Compounds; Bortezomib; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Expression; Glycine; Histone Deacetylases; Humans; Indoles; Models, Biological; Multiple Myeloma; Mutation; Oligopeptides; Panobinostat; Phosphatidylinositol 3-Kinase; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrimidines; Thiazoles | 2019 |
Cost-effectiveness analysis on binary/triple therapy on the basis of ixazomib or bortezomib for refractory or relapsed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Cost-Benefit Analysis; Drug Costs; Drug Resistance, Neoplasm; Glycine; Health Care Costs; Humans; Multiple Myeloma; Quality of Life; Quality-Adjusted Life Years; Recurrence; Treatment Outcome | 2019 |
[Efficacy and Safety of Ixazomib-Lenalidomide-Dexamethasone Therapy for Relapsed and Refractory Multiple Myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Glycine; Humans; Japan; Lenalidomide; Multiple Myeloma; Retrospective Studies | 2019 |
Venetoclax in Immunoglobulin Light Chain Amyloidosis: Is This the Beginning or the End?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Bridged Bicyclo Compounds, Heterocyclic; Dexamethasone; Glycine; Humans; Immunoglobulin Light Chains; Immunoglobulin Light-chain Amyloidosis; Male; Remission Induction; Sulfonamides | 2019 |
Combinatorial ixazomib and belinostat therapy induces NFE2L2-dependent apoptosis in Hodgkin and T-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boron Compounds; Cell Line, Tumor; Down-Regulation; Drug Synergism; Glycine; Hodgkin Disease; Humans; Hydroxamic Acids; Jurkat Cells; Lymphoma, T-Cell; NF-E2-Related Factor 2; Sulfonamides | 2020 |
Ixazomib-induced Sweet's syndrome.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Glycine; Humans; Lenalidomide; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Sweet Syndrome | 2019 |
The Zinc-Finger AN1-Type Domain 2a Gene Acts as a Regulator of Cell Survival in Human Melanoma: Role of E3-Ligase cIAP2.
Topics: Baculoviral IAP Repeat-Containing 3 Protein; Boron Compounds; Bortezomib; Cell Line, Tumor; Cell Transformation, Neoplastic; Gene Expression Regulation, Neoplastic; Glycine; Heat Shock Transcription Factors; Humans; Melanoma; Myeloid Cells; Oligopeptides; Proteasome Endopeptidase Complex; RNA-Binding Proteins; Spheroids, Cellular | 2019 |
Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Glycine; Humans; Multiple Myeloma; Quality of Life; Thalidomide | 2020 |
Ixazomib-induced Sweet's syndrome.
Topics: Boron Compounds; Glycine; Humans; Sweet Syndrome | 2020 |
Use of ixazomib, lenalidomide and dexamethasone in patients with relapsed amyloid light-chain amyloidosis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Female; Glycine; Humans; Immunoglobulin Light-chain Amyloidosis; Lenalidomide; Male; Middle Aged; Neoplasm Recurrence, Local | 2020 |
Discovery of Novel Peptidomimetic Boronate ClpP Inhibitors with Noncanonical Enzyme Mechanism as Potent Virulence Blockers
Topics: Animals; Anti-Bacterial Agents; Bacterial Proteins; Boron Compounds; Boronic Acids; Endopeptidase Clp; Female; Glycine; Humans; Methicillin-Resistant Staphylococcus aureus; Mice, Inbred BALB C; Molecular Docking Simulation; Molecular Structure; Peptidomimetics; Protein Binding; Serine Proteinase Inhibitors; Skin; Small Molecule Libraries; Staphylococcal Skin Infections; Structure-Activity Relationship; Virulence | 2020 |
c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boron Compounds; Dexamethasone; Female; Gene Expression; Gene Expression Profiling; Glycine; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Grading; Neoplasm Staging; Prognosis; Progression-Free Survival; Proto-Oncogene Proteins c-myc; Treatment Outcome | 2020 |
Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Data Analysis; Female; Follow-Up Studies; Glycine; Humans; Israel; Male; Middle Aged; Multiple Myeloma; Pragmatic Clinical Trials as Topic; Recurrence; Registries; Treatment Outcome | 2020 |
Differential antitumor activity of compounds targeting the ubiquitin-proteasome machinery in gastrointestinal stromal tumor (GIST) cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boron Compounds; Boronic Acids; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Glycine; Humans; Imatinib Mesylate; Male; Mice; Mice, Nude; Oligopeptides; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Signal Transduction; Threonine; Xenograft Model Antitumor Assays | 2020 |
Medication use evaluation of the financial and clinical implications of ixazomib compared to bortezomib in the outpatient setting.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Agents; Boron Compounds; Bortezomib; Drug Costs; Female; Glycine; Humans; Injections, Subcutaneous; Insurance, Health, Reimbursement; Male; Middle Aged; Multiple Myeloma; Retrospective Studies | 2021 |
Clinical study on ixazomib in the treatment of multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Glycine; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Treatment Outcome | 2020 |
Efficacy of ixazomib for the treatment of relapsed/refractory multiple myeloma: A protocol of systematic review and meta-analysis.
Topics: Boron Compounds; Clinical Protocols; Glycine; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Treatment Outcome | 2020 |
Inhibition of chymotrypsin-like activity of the proteasome by ixazomib prevents mitochondrial dysfunction during myocardial ischemia.
Topics: Animals; Boron Compounds; Chymotrypsin; Disease Models, Animal; Glutathione; Glycine; Heart; Humans; Membrane Potentials; Mitochondria; Myocardial Ischemia; Oxygen Consumption; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Rats | 2020 |
The proteostasis guardian HSF1 directs the transcription of its paralog and interactor HSF2 during proteasome dysfunction.
Topics: Boron Compounds; Bortezomib; Cell Line, Tumor; Cell Movement; Cell Nucleus; Electrophoretic Mobility Shift Assay; Glycine; Heat Shock Transcription Factors; Heat-Shock Proteins; Humans; Promoter Regions, Genetic; Proteasome Endopeptidase Complex; Proteasome Inhibitors; RNA Interference; RNA, Messenger; RNA, Small Interfering; Transcription Factors; Transcription Initiation Site; Transcription, Genetic | 2021 |
Ixazomib Treatment of IgA Multiple Myeloma With Hyperviscosity Syndrome.
Topics: Aged; Blood Viscosity; Boron Compounds; Female; Glycine; Humans; Multiple Myeloma; Syndrome; Treatment Outcome | 2020 |
Patient Characteristics and Outcomes of Relapsed/Refractory Multiple Myeloma in Patients Treated with Proteasome Inhibitors in Germany.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Dexamethasone; Female; Germany; Glycine; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Progression-Free Survival; Proteasome Inhibitors; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2020 |
[Systemic varicella-zoster infection during ixazomib-containing multiagent chemotherapy for multiple myeloma].
Topics: Boron Compounds; Chickenpox; Glycine; Herpes Zoster; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local | 2020 |
Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Female; Glycine; Humans; Male; Multiple Myeloma; Progression-Free Survival; Proteasome Inhibitors; Survival Analysis; Treatment Outcome | 2020 |
Phosphorylation-dependent osterix degradation negatively regulates osteoblast differentiation.
Topics: Animals; Boron Compounds; Bortezomib; Cell Differentiation; Cells, Cultured; F-Box-WD Repeat-Containing Protein 7; Glycine; HCT116 Cells; HEK293 Cells; Humans; Mice; Osteoblasts; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteolysis; Sp7 Transcription Factor; Ubiquitination | 2020 |
A Promising New Therapy of Oral Ixazomib Without Rituximab for Waldenstrom Macroglobulinemia
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Boron Compounds; Female; Glycine; Humans; Protease Inhibitors; Rituximab; Tomography, X-Ray Computed; Treatment Outcome; Waldenstrom Macroglobulinemia | 2021 |
Ixazomib-associated tumor lysis syndrome in multiple myeloma: A case report.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Fatal Outcome; Female; Glycine; Humans; Middle Aged; Multiple Myeloma; Tumor Lysis Syndrome | 2020 |
Ixazomib and lenalidomide maintenance therapy in multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Female; Glycine; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma | 2021 |
Ixazomib, an oral proteasome inhibitor, exhibits potential effect in dystrophin-deficient mdx mice.
Topics: Animals; Boron Compounds; Dystrophin; Glycine; Mice, Inbred mdx; Muscle, Skeletal; Muscular Dystrophy, Duchenne; Protease Inhibitors; Utrophin | 2021 |
Ixazomib, lenalidomide, and dexamethasone is effective and well tolerated in multiply relapsed (≥2nd relapse) refractory myeloma: a multicenter real world UK experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Glycine; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; United Kingdom | 2021 |
Ixazomib with lenalidomide and dexamethasone for patients with relapsed multiple myeloma: impact of 17p deletion and sensitivity to proteasome inhibitors from a real world data-set.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Glycine; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Proteasome Inhibitors | 2021 |
Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Czech Republic; Dexamethasone; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Glycine; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Progression-Free Survival; Prospective Studies; Registries | 2021 |
Outcomes of ixazomib/lenalidomide/dexamethasone for multiple myeloma: A multicenter retrospective analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boron Compounds; Dexamethasone; Female; Glycine; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Retreatment; Retrospective Studies; Treatment Outcome | 2021 |
Oxidatively modified low-density lipoproteins are potential mediators of proteasome inhibitor resistance in multiple myeloma.
Topics: Boron Compounds; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Glycine; Granulocytes; Humans; Lipid Peroxides; Lipoproteins, LDL; Monocytes; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors | 2021 |
Resolution of bortezomib-associated chalazia/blepharitis after switch to ixazomib: A case report.
Topics: Blepharitis; Boron Compounds; Bortezomib; Chalazion; Glycine; Humans | 2021 |
Ixazomib inhibits myeloma cell proliferation by targeting UBE2K.
Topics: Apoptosis; Biomarkers, Tumor; Boron Compounds; Cell Line, Tumor; Cell Proliferation; Cell Survival; Gene Expression Regulation, Neoplastic; Glycine; Humans; Mitosis; Multiple Myeloma; Ubiquitin-Conjugating Enzymes | 2021 |
Discovery of novel candidates for anti-liposarcoma therapies by medium-scale high-throughput drug screening.
Topics: Acrylamides; Antineoplastic Agents; Biomarkers, Pharmacological; Boron Compounds; Cell Line, Tumor; Diterpenes; Drug Evaluation, Preclinical; Epoxy Compounds; Glycine; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Imidazoles; Liposarcoma; Naphthoquinones; Phenanthrenes; Piperidines; Pyridazines; Quinolines; Small Molecule Libraries; Sulfonamides | 2021 |
Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells.
Topics: Boron Compounds; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Glycine; Humans; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proteasome Endopeptidase Complex; Proteasome Inhibitors | 2021 |
Ixazomib as treatment for pyoderma gangrenosum associated with IgA smoldering multiple myeloma.
Topics: Aged; Antineoplastic Agents; Boron Compounds; Glycine; Humans; Immunoglobulin A; Male; Pyoderma Gangrenosum; Smoldering Multiple Myeloma | 2022 |
Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Female; Glycine; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Retrospective Studies; Treatment Outcome | 2021 |
Oral Proteasome Inhibitor Ixazomib for Switch-Maintenance Prophylaxis of Recurrent or Late Acute and Chronic Graft-versus-Host Disease after Day 100 in Allogeneic Stem Cell Transplantation.
Topics: Boron Compounds; Glycine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Neoplasm Recurrence, Local; Pilot Projects; Prospective Studies; Proteasome Inhibitors | 2021 |
M3258 Is a Selective Inhibitor of the Immunoproteasome Subunit LMP7 (β5i) Delivering Efficacy in Multiple Myeloma Models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boron Compounds; Boronic Acids; Bortezomib; Cell Proliferation; Drug Resistance, Neoplasm; Female; Furans; Gene Expression Regulation, Neoplastic; Glycine; Humans; Mice; Mice, Nude; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteolysis; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |
Sweet Syndrome Associated with Ixazomib
Topics: Boron Compounds; Glycine; Humans; Sweet Syndrome | 2021 |
Retrospective study of treatment patterns and outcomes post-lenalidomide for multiple myeloma in Canada.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Canada; Dexamethasone; Female; Glycine; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Recurrence; Retrospective Studies; Salvage Therapy; Survival Analysis; Thalidomide; Transplantation, Autologous | 2021 |
Up-front ixazomib in older patients with myeloma.
Topics: Aged; Boron Compounds; Glycine; Humans; Multiple Myeloma | 2021 |
Long-time progression-free survival in relapsed, refractory multiple myeloma with the oral ixazomib-lenalidomide-dexamethasone regime
Topics: Boron Compounds; Dexamethasone; Glycine; Humans; Lenalidomide; Multiple Myeloma; Progression-Free Survival; Retrospective Studies | 2021 |
Ixazomib, lenalidomide, and dexamethasone combination in "real-world" clinical practice in patients with relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Cohort Studies; Dexamethasone; Female; Glycine; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Slovakia | 2022 |
Delayed administration of ixazomib modifies the immune response and prevents chronic graft-versus-host disease.
Topics: Animals; Bone Marrow Transplantation; Boron Compounds; Glycine; Graft vs Host Disease; Graft vs Leukemia Effect; Immunity; Mice | 2021 |
Safety Profile of Ixazomib in Patients with Relapsed/Refractory Multiple Myeloma in Japan: An All-case Post-marketing Surveillance.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Diarrhea; Glycine; Humans; Japan; Leukopenia; Middle Aged; Multiple Myeloma; Product Surveillance, Postmarketing; Thalidomide; Thrombocytopenia | 2022 |
Ixazomib-based maintenance therapy after bortezomib-based induction in patients with multiple myeloma not undergoing transplantation: A real-world study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Dexamethasone; Glycine; Humans; Multiple Myeloma; Retrospective Studies; Treatment Outcome | 2022 |
Ixazomib Induces Apoptosis and Suppresses Proliferation in Esophageal Squamous Cell Carcinoma through Activation of the c-Myc/NOXA Pathway.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boron Compounds; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Esophageal Neoplasms; Glycine; Humans; Mice; Mice, Inbred BALB C; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc | 2022 |
High Immunoproteasome Activity and sXBP1 in Pediatric Precursor B-ALL Predicts Sensitivity towards Proteasome Inhibitors.
Topics: Boron Compounds; Bortezomib; Cell Death; Child; Gene Expression Regulation, Leukemic; Glycine; Humans; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Subunits; RNA, Messenger; X-Box Binding Protein 1 | 2021 |
Inhibition of cytoplasmic EZH2 induces antitumor activity through stabilization of the DLC1 tumor suppressor protein.
Topics: Animals; Antineoplastic Agents; Benzodioxoles; Boron Compounds; Cell Line, Tumor; Enhancer of Zeste Homolog 2 Protein; Gene Knockdown Techniques; Gene Knockout Techniques; Glycine; GTPase-Activating Proteins; HEK293 Cells; Heterocyclic Compounds, 3-Ring; Humans; Lung Neoplasms; Mice; Mutagenesis, Site-Directed; Phosphorylation; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Kinase Inhibitors; Protein Stability; Proto-Oncogene Proteins p21(ras); Quinazolines; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2021 |
[Efficacy of total oral regimens containing ixazomib in patients with relapsed and refractory multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Glycine; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Retrospective Studies | 2022 |
Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Patients with Posttransplant Myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Glycine; Humans; Lenalidomide; Multiple Myeloma | 2022 |
Ixazomib in addition to chemotherapy for the treatment of acute lymphoblastic leukemia in older adults.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Glycine; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Treatment Outcome; Vincristine | 2022 |
Structural basis to repurpose boron-based proteasome inhibitors Bortezomib and Ixazomib as β-lactamase inhibitors.
Topics: beta-Lactamase Inhibitors; Boron; Boron Compounds; Bortezomib; Glycine; Proteasome Inhibitors | 2022 |
Comprehensive Analysis of Ixazomib-Induced Adverse Events Using the Japanese Pharmacovigilance Database.
Topics: Boron Compounds; Glycine; Humans; Japan; Multiple Myeloma; Pharmacovigilance | 2022 |
Population pharmacokinetic/pharmacodynamic joint modeling of ixazomib efficacy and safety using data from the pivotal phase III TOURMALINE-MM1 study in multiple myeloma patients.
Topics: Boron Compounds; Clinical Trials, Phase III as Topic; Diarrhea; Exanthema; Glycine; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Prospective Studies; Silicates | 2022 |
[Ixazomib-Based Regimen Followed by Autologous Hematopoietic Stem Cell Transplantation in the Treatment of POEMS Syndrome].
Topics: Adult; Boron Compounds; Glycine; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; POEMS Syndrome; Retrospective Studies; Transplantation, Autologous; Vascular Endothelial Growth Factor A | 2022 |
High-Throughput Screening of FDA-Approved Drug Library Reveals Ixazomib Is a Broad-Spectrum Antiviral Agent against Arboviruses.
Topics: Animals; Antiviral Agents; Arboviruses; Boron Compounds; Chikungunya virus; Citrates; Glycine; High-Throughput Screening Assays; Humans; Mice | 2022 |
Combined Therapy with Ixazomib, Lenalidomide, and Dexamethasone for Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes Syndrome.
Topics: Boron Compounds; Dexamethasone; Endocrine System Diseases; Glycine; Humans; Lenalidomide; Monoclonal Gammopathy of Undetermined Significance; POEMS Syndrome; Vascular Endothelial Growth Factor A | 2022 |
An update on the safety of ixazomib for the treatment of multiple myeloma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Glycine; Humans; Multiple Myeloma; Proteasome Inhibitors; Quality of Life | 2022 |
Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemia.
Topics: Adult; Aged; Boron Compounds; Bortezomib; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Glycine; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Kinase Inhibitors | 2022 |
The UHPLC-UV method applied for the forced degradation study of ixazomib and HRMS identification of its degradation products.
Topics: Antineoplastic Agents; Boron Compounds; Chromatography, High Pressure Liquid; Drug Stability; Glycine; Hydrolysis; Oxidation-Reduction; Proteasome Inhibitors | 2023 |
[Analysis of the efficacy and survival of ixazomib-containing regimens in patients with refractory and relapsed multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Glycine; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local | 2022 |
LINC00461 Knockdown Enhances the Effect of Ixazomib in Multiple Myeloma Cells.
Topics: Apoptosis; Boron Compounds; Cell Line, Tumor; Glycine; Humans; Multiple Myeloma | 2023 |
Inhibitory Effort of MLN2238 on Basal-Like Breast Cancer: An Investigation Based on the Gene Set Enrichment Analysis.
Topics: Breast Neoplasms; Cell Cycle; Cell Division; Female; Glycine; Humans | 2023 |